🏷

Classifications

Harrison's Chapter

⚙

Pathophysiology

7

NAGS molecular function deficiency

NAGS catalyzes N-acetylglutamate (NAG) formation from acetyl-CoA and L-glutamate in the mitochondrial matrix of hepatocytes and intestinal cells. Loss of NAGS activity reduces NAG availability, creating the primary biochemical lesion in NAGS deficiency.

hepatocyte link

NAGS link

N-acetylglutamate synthase activity link ↓ DECREASED

mitochondrion link liver link

Downstream

N-acetylglutamate (NAG) Loss of NAGS enzyme activity lowers production of N-acetylglutamate, the endogenous CPS1 activator.

Loss of CPS1 activation and impaired ureagenesis NAG depletion prevents normal allosteric activation of CPS1.

Show evidence (2 references)

PMID:26068232 SUPPORT Other

"N-acetylglutamate synthase (NAGS) catalyzes the production of N-acetylglutamate (NAG) from acetyl-CoA and L-glutamate."

Directly supports NAGS as the enzyme responsible for NAG production.

PMID:38740568 SUPPORT In Vitro

"N-acetylglutamate synthase (NAGS) makes acetylglutamate, the essential activator of the first, regulatory enzyme of the urea cycle, carbamoyl phosphate synthetase 1 (CPS1)."

Supports the mechanistic dependency of CPS1 activation on NAG production by NAGS.

Loss of CPS1 activation and impaired ureagenesis

NAG is the obligate allosteric activator of CPS1. When NAG is deficient, CPS1 remains underactivated, reducing carbamoyl phosphate formation and impairing proximal urea cycle flux.

urea cycle link

mitochondrion link liver link

Downstream

Systemic hyperammonemia and glutamine diversion Impaired ureagenesis prevents hepatic ammonia disposal, producing the proximal-UCD biochemical profile.

Show evidence (2 references)

PMID:27570737 SUPPORT Human Clinical

"Carbamoylphosphate synthetase 1 (CPS1), the first and rate-limiting enzyme of urea cycle, is activated by N-acetylglutamate (NAG), and thus N-acetylglutamate synthase (NAGS) is an essential part of the urea cycle."

Directly supports the NAG-CPS1 dependency and proximal urea cycle block when NAGS is deficient.

PMID:38637895 SUPPORT Human Clinical

"Hyperammonemic crises can be avoided in individuals with NAGS deficiency by the administration of carbamylglutamate (also known as carglumic acid), which activates carbamoyl phosphatase synthetase 1 (CPS1)."

Clinical response to CPS1 activation supports CPS1 underactivation as a causal step.

Systemic hyperammonemia and glutamine diversion

Reduced NAG-dependent CPS1 activation impairs hepatic nitrogen disposal. Ammonia and glutamine rise, citrulline falls, and urinary orotic acid remains normal to low, creating the systemic biochemical state that drives acute decompensation.

urea cycle link

liver link

Downstream

Plasma ammonia Failed hepatic ureagenesis manifests biochemically as increased circulating ammonia.

Plasma glutamine Excess nitrogen is diverted into glutamine, increasing plasma glutamine.

Plasma citrulline Reduced CPS1 activation limits carbamoyl phosphate availability for downstream citrulline synthesis.

Urine orotic acid The proximal urea-cycle block leaves urinary orotic acid normal to low, distinguishing NAGS/CPS1 deficiency from OTC deficiency.

Hyperammonemia Systemic ammonia accumulation is the defining clinical biochemical phenotype.

Vomiting Acute hyperammonemic decompensation can present with nausea and vomiting.

Lethargy Hyperammonemic NAGS deficiency can present with reduced alertness and lethargy.

Headache Late-onset NAGS deficiency can manifest with recurrent headaches driven by hyperammonemia and/or hypoargininemia.

Respiratory alkalosis Neonatal urea-cycle hyperammonemia can first present with tachypnea and respiratory alkalosis.

Hyperammonemic astrocyte stress and glutamine accumulation Circulating ammonia crosses into the CNS and is converted to glutamine in astrocytes.

Show evidence (1 reference)

PMID:29364180 SUPPORT Human Clinical

"Clinically and biochemically, NAGSD is indistinguishable from CPS1 deficiency (CPS1D), and common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid"

Supports the systemic proximal-UCD biochemical profile caused by NAGS deficiency.

Impaired arginine-mediated NAGS regulation

NAGS activity is allosterically regulated by L-arginine, which increases enzyme activity 2-5-fold under physiological conditions. Many disease-causing NAGS variants show loss of arginine activation as their primary mechanistic defect. Hampered NAGS activation by arginine has emerged as a paramount causative factor of NAGS deficiency.

urea cycle link positive regulation of catalytic activity link

Downstream

Loss of CPS1 activation and impaired ureagenesis Loss of arginine-mediated NAGS activation further reduces NAG-dependent CPS1 activation.

Show evidence (1 reference)

PMID:27934952 SUPPORT In Vitro

"L-arginine inhibits NAGS in bacteria, fungi, and plants and activates NAGS in mammals."

Confirms that L-arginine is a positive regulator of mammalian NAGS activity.

Hyperammonemic astrocyte stress and glutamine accumulation

Hyperammonemia drives encephalopathy and astrocyte stress in the brain. Ammonia detoxification in astrocytes increases glutamine production, creating intracellular osmotic burden and vulnerability to swelling.

astrocyte link

glutamine biosynthetic process link

brain link

Downstream

Seizures Hyperammonemic CNS stress can cause epileptiform activity and seizures during decompensation.

Cytotoxic cerebral edema and intracranial hypertension Astrocytic osmotic stress can progress to cerebral edema and life-threatening intracranial complications.

Encephalopathy Astrocyte ammonia/glutamine stress produces acute hyperammonemic encephalopathy.

Show evidence (1 reference)

PMID:33179600 PARTIAL Human Clinical

"Newborns who are often affected by hyper-ammonaemic encephalopathy carry a potential risk of severe brain damage, which may lead to death."

Supports severe hyperammonemic encephalopathy as the upstream neurotoxic state.

Cytotoxic cerebral edema and intracranial hypertension

In severe crises, ammonia-mediated brain injury progresses to cerebral edema, intracranial hypertension, and risk of herniation, coma, and death.

brain link

Downstream

Cerebral edema Intracranial hypertension and brain swelling manifest clinically as cerebral edema.

Coma Raised intracranial pressure from severe ammonia neurotoxicity can progress to coma.

Intellectual disability Severe or recurrent hyperammonemic brain injury can leave lasting cognitive sequelae.

Show evidence (2 references)

PMID:33409766 SUPPORT Human Clinical

"Awareness of urea cycle disorders in adults intensive care units can optimize early management and accordingly dramatically improve prognosis. By preventing hyperammonemia to induce brain edema and herniation leading to death."

Directly supports progression from hyperammonemia to cerebral edema and herniation.

PMID:33179600 SUPPORT Human Clinical

"Newborns who are often affected by hyper-ammonaemic encephalopathy carry a potential risk of severe brain damage, which may lead to death."

Supports severe neurological outcomes in untreated neonatal hyperammonemic crises.

Variant-specific biochemical mechanisms of NAGS dysfunction

Functional characterization of 23 patient-derived NAGS missense variants using stabilized recombinant human enzyme has identified multiple mechanistic classes of pathogenicity including loss of arginine activation, increased Km for glutamate, active site inactivation, decreased thermal stability, and protein misfolding. This approach outperforms bacterial surrogate enzymes and in silico prediction tools for assessing pathogenicity and guiding therapeutic decisions.

Downstream

NAGS molecular function deficiency Patient-derived missense variants reduce NAGS enzyme function by multiple biochemical mechanisms.

Impaired arginine-mediated NAGS regulation Loss of arginine activation is one functional class of pathogenic NAGS variant.

Show evidence (2 references)

PMID:38740568 SUPPORT In Vitro

"Our present approach outperforms experimental in vitro use of bacterial NAGS or in silico utilization of prediction servers (including AlphaMissense), illustrating with HuNAGS the value for UCDs of using recombinant enzymes for assessing disease-causation and molecular pathogenesis, and for..."

Validates the recombinant human enzyme approach for functional variant characterization.

PMID:38740568 SUPPORT In Vitro

"For all but one change, disease causation was accounted by the enzymatic alterations identified, including, depending on the variant, loss of arginine activation, increased Km Glutamate, active site inactivation, decreased thermal stability, and protein misfolding."

Defines the variant-level enzyme mechanisms that feed into NAGS dysfunction.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

11

Digestive 1

Vomiting FREQUENT Vomiting (HP:0002013)

Show evidence (1 reference)

PMID:29364180 SUPPORT Human Clinical

"headaches had been present since puberty (3-4 days a week) and were often accompanied by nausea, vomiting, or behavioural changes."

Documents vomiting as a recurrent symptom in a late-onset NAGS deficiency case.

Metabolism 3

Hyperammonemia VERY_FREQUENT Hyperammonemia (HP:0001987)

Show evidence (2 references)

PMID:33036647 SUPPORT Human Clinical

"N-Acetylglutamate synthase (NAGS) deficiency is an extremely rare autosomal recessive metabolic disorder affecting the urea cycle, leading to episodes of hyperammonemia which can cause significant morbidity and mortality."

Directly identifies hyperammonemia as the defining feature of NAGS deficiency.

PMID:38637895 SUPPORT Human Clinical

"Hyperammonemic crises can be avoided in individuals with NAGS deficiency by the administration of carbamylglutamate (also known as carglumic acid), which activates carbamoyl phosphatase synthetase 1 (CPS1)."

Confirms hyperammonemic crises as the key clinical problem in NAGS deficiency.

Cerebral edema OCCASIONAL Cerebral edema (HP:0002181)

Show evidence (1 reference)

PMID:33409766 SUPPORT Human Clinical

"By preventing hyperammonemia to induce brain edema and herniation leading to death."

Directly supports cerebral edema as a consequence of hyperammonemia in UCDs.

Respiratory alkalosis OCCASIONAL Respiratory alkalosis (HP:0001950)

Respiratory alkalosis from hyperventilation is a recognized feature of acute hyperammonemia in urea cycle disorders generally but specific frequency data for NAGS deficiency are limited.

Show evidence (1 reference)

PMID:33113778 SUPPORT Human Clinical

"We report a series of three newborns presenting irritability, poor feeding and tachypnea. Their first gas analysis revealed respiratory alkalosis. Hyperammonemia was confirmed, and three different enzymatic blocks in the urea cycle were diagnosed."

Human neonatal UCD cases support respiratory alkalosis as an early hyperammonemia presentation.

Nervous System 6

Encephalopathy VERY_FREQUENT Encephalopathy (HP:0001298)

Show evidence (1 reference)

PMID:33179600 SUPPORT Human Clinical

"Newborns who are often affected by hyper-ammonaemic encephalopathy carry a potential risk of severe brain damage, which may lead to death."

Directly supports hyperammonemic encephalopathy as a common severe presentation of UCDs.

Lethargy FREQUENT Lethargy (HP:0001254)

Show evidence (1 reference)

PMID:33179600 SUPPORT Human Clinical

"Outside the neonatal period, symptoms are very unspecific but most often neurological (with wide variability), psychiatric and/or gastrointestinal."

Supports neurological symptoms including altered consciousness in UCDs.

Seizures OCCASIONAL Seizure (HP:0001250)

Show evidence (1 reference)

PMID:38637895 SUPPORT Human Clinical

"once due to seizure activity limiting the family's ability to administer carbamylglutamate."

Documents seizure activity in a patient with NAGS deficiency.

Intellectual disability OCCASIONAL Intellectual disability (HP:0001249)

Show evidence (1 reference)

PMID:38637895 SUPPORT Human Clinical

"One patient experienced two episodes of hyperammonemia that resulted in poor long-term outcomes."

Documents poor long-term outcomes from hyperammonemic episodes in NAGS deficiency.

Headache OCCASIONAL Headache (HP:0002315)

Show evidence (1 reference)

PMID:29364180 SUPPORT Human Clinical

"The manuscript underlies that headache may be the presenting symptom of UCDs and provides clues for the rapid diagnosis and treatment of late-onset NAGSD."

Highlights headache as a diagnostically important symptom in late-onset NAGS deficiency.

Coma OCCASIONAL Coma (HP:0001259)

Show evidence (1 reference)

PMID:29364180 SUPPORT Human Clinical

"Despite three previous episodes of altered consciousness, ammonia was measured for the first time at 52 years and levels were increased."

Documents recurrent episodes of altered consciousness before NAGS deficiency diagnosis.

Growth 1

Failure to thrive FREQUENT Failure to thrive (HP:0001508)

Failure to thrive is well-documented in neonatal-onset UCD presentations. The NAGS systematic review (PMID:33036647, 98 cases) describes the clinical spectrum including 57 neonatal cases, but the abstract does not specifically quantify FTT frequency.

🧬

Genetic Associations

1

NAGS pathogenic variants

Autosomal recessive

Show evidence (3 references)

PMID:33036647 SUPPORT Human Clinical

"In total, 98 cases of NAGS deficiency from 79 families, in 48 articles or abstracts were identified."

Documents the breadth of reported NAGS deficiency cases and families with diverse variants.

PMID:38740568 SUPPORT In Vitro

"NAGSD is cured by substitutive therapy with the N-acetyl-L-glutamate analogue N-carbamyl-L-glutamate, while curative therapy of CPS1D requires liver transplantation. Since their differentiation is done genetically, it is important to ascertain the disease-causing potential of CPS1 and NAGS..."

Emphasizes the critical importance of genetic characterization for differentiating NAGS deficiency from CPS1 deficiency.

CGGV:assertion_33dcead1-e3d9-4427-98fd-05a655c8c213-2019-07-26T160000.000Z SUPPORT Other

ClinGen classifies the NAGS-hyperammonemia due to N-acetylglutamate synthase deficiency gene-disease relationship as definitive with autosomal recessive inheritance.

💊

Treatments

8

Carglumic acid (N-carbamyl-L-glutamate)

Action: pharmacotherapy MAXO:0000058

Agent: carglumic acid ↗

Carglumic acid is a synthetic stable analogue of N-acetylglutamate that directly activates CPS1, bypassing deficient NAGS and restoring urea cycle flux. It is the specific disease-modifying therapy for NAGS deficiency and the only urea cycle disorder that can be cured by substitutive drug therapy. All patients in the 2024 case series responded well to carbamylglutamate therapy, with normalization of ammonia, citrulline, and orotic acid.

Mechanism Target:

RESTORES Loss of CPS1 activation and impaired ureagenesis — Carglumic acid is a stable NAG analogue that activates CPS1 despite deficient NAGS activity.

Show evidence (1 reference)

PMID:27570737 SUPPORT Human Clinical

"Although NAGS deficiency is the rarest urea cycle disorder, it is the only one that can be specifically and effectively treated by a drug, N-carbamylglutamate, a stable structural analogous of NAG that activates CPS1."

Directly supports carglumic acid as a CPS1-activating NAG analogue.

INHIBITS Systemic hyperammonemia and glutamine diversion — Restored CPS1 activation improves urea-cycle flux and normalizes hyperammonemia-associated biochemical abnormalities.

Show evidence (1 reference)

PMID:38637895 SUPPORT Human Clinical

"All patients responded well to carbamylglutamate therapy, as indicated by normalization of plasma ammonia and citrulline, as well as urine orotic acid in patients with abnormal levels at baseline."

Clinical response shows inhibition of the systemic biochemical decompensation state.

Show evidence (3 references)

PMID:38637895 SUPPORT Human Clinical

"All patients responded well to carbamylglutamate therapy, as indicated by normalization of plasma ammonia and citrulline, as well as urine orotic acid in patients with abnormal levels at baseline."

Directly demonstrates efficacy of carbamylglutamate in normalizing biochemical parameters.

PMID:27570737 SUPPORT Human Clinical

"Although NAGS deficiency is the rarest urea cycle disorder, it is the only one that can be specifically and effectively treated by a drug, N-carbamylglutamate, a stable structural analogous of NAG that activates CPS1."

Establishes carglumic acid as the specific curative drug for NAGS deficiency.

PMID:38740568 SUPPORT In Vitro

"NAGSD is cured by substitutive therapy with the N-acetyl-L-glutamate analogue N-carbamyl-L-glutamate"

Confirms NAGS deficiency is cured by substitutive therapy with carglumic acid.

Dietary protein management

Action: dietary intervention MAXO:0000088

Although protein restriction was historically used, carbamylglutamate therapy allows most patients to liberalize their diets. However, protein restriction remains an important strategy during illness or disruption of medication access. The maximum safe level of protein intake to prevent hyperammonemia is not yet known.

Mechanism Target:

INHIBITS Systemic hyperammonemia and glutamine diversion — Protein restriction reduces nitrogen substrate load during illness or when pharmacologic control is uncertain.

Show evidence (1 reference)

PMID:38637895 SUPPORT Human Clinical

"Carbamylglutamate can help patients with NAGS deficiency to liberalize their diets, but the maximum safe level of protein intake to prevent hyperammonemia is not yet known."

Supports dietary protein management as an ammonia-prevention strategy.

Show evidence (3 references)

PMID:38637895 SUPPORT Human Clinical

"Although protein restriction was not prescribed in any cases after carbamylglutamate initiation, two patients continued to self-restrict protein intake."

Documents that protein restriction is not routinely needed with carbamylglutamate but remains a consideration.

PMID:38637895 SUPPORT Human Clinical

"Carbamylglutamate can help patients with NAGS deficiency to liberalize their diets, but the maximum safe level of protein intake to prevent hyperammonemia is not yet known."

Highlights the evolving role of dietary management alongside pharmacotherapy.

PMID:33036647 SUPPORT Human Clinical

"Management usually consists of treatment with carbamylglutamate, although the reported maintenance dose varied across case reports. Protein restriction was sometimes used in conjunction with carbamylglutamate."

Confirms variable use of protein restriction alongside drug therapy.

Nitrogen scavenger therapy

Action: nitrogen scavenger therapy Ontology label: pharmacotherapy MAXO:0000058

Agent: sodium benzoate ↗ sodium phenylbutyrate ↗

Sodium benzoate, sodium phenylacetate, or sodium phenylbutyrate may be used as adjunctive ammonia-lowering agents during acute hyperammonemic crises. These drugs provide alternative nitrogen disposal pathways independent of the urea cycle.

Mechanism Target:

BYPASSES Systemic hyperammonemia and glutamine diversion — Nitrogen scavengers route waste nitrogen into urinary excretion pathways that do not require normal urea-cycle flux.

Show evidence (1 reference)

PMID:33409766 SUPPORT Human Clinical

"Ammonia is diverted to the glycine and hippuric acid pathway by benzoate, and to the glutamine and phenylacetylglutamine pathway allowing elimination in the urine without passing through the urea cycle"

Clinical UCD management review directly supports the bypass mechanism for ammonia scavengers.

Show evidence (2 references)

PMID:33036647 SUPPORT Human Clinical

"Since its recognition in 1981, NAGS deficiency has been treated with carbamylglutamate with or without other measures (nutritional, ammonia scavengers, dialytic, etc.)."

Confirms the use of nitrogen scavengers as part of NAGS deficiency management.

PMID:33179600 SUPPORT Human Clinical

"The acute management includes detoxification of ammonia, which often requires extracorporeal means such as haemodialysis, and the use of intravenous drugs that work as nitrogen scavengers."

Supports the use of nitrogen scavengers in acute hyperammonemia management.

Extracorporeal ammonia removal

Action: hemodialysis MAXO:0000602

Hemodialysis or continuous venovenous hemofiltration (CVVH) may be required for emergency ammonia removal during severe hyperammonemic crises, particularly when ammonia levels exceed 200 micromol/L or when pharmacological measures are insufficient.

Mechanism Target:

INHIBITS Systemic hyperammonemia and glutamine diversion — Dialysis rapidly removes ammonia during severe hyperammonemic crises.

Show evidence (1 reference)

PMID:33179600 SUPPORT Human Clinical

"The acute management includes detoxification of ammonia, which often requires extracorporeal means such as haemodialysis, and the use of intravenous drugs that work as nitrogen scavengers."

Supports extracorporeal ammonia detoxification as an acute mechanism-directed treatment.

Show evidence (2 references)

PMID:33179600 SUPPORT Human Clinical

"The acute management includes detoxification of ammonia, which often requires extracorporeal means such as haemodialysis, and the use of intravenous drugs that work as nitrogen scavengers."

Directly supports use of hemodialysis for acute ammonia removal in UCDs.

PMID:33409766 SUPPORT Human Clinical

"Treatment consists in adapted nutrition, scavenging agents and dialysis. As adults are more susceptible to hyperammonemia, emergent hemodialysis is mandatory before referral to a reference center if ammonia levels are above 200 µmol/l"

Establishes dialysis threshold and its role in acute UCD management.

Supportive care during acute crises

Action: supportive care MAXO:0000950

Emergency management of hyperammonemic crises includes cessation of protein intake, reversal of catabolism via high-calorie glucose infusion, correction of dehydration and electrolyte imbalances, and intensive care monitoring. Plans for illness and medication access disruption should be established for all patients.

Mechanism Target:

INHIBITS Systemic hyperammonemia and glutamine diversion — Crisis plans and anticatabolic supportive measures reduce ammonia generation and prevent recurrent hyperammonemic decompensation.

Show evidence (1 reference)

PMID:38637895 SUPPORT Human Clinical

"Follow-up of patients with NAGS deficiency should include plans for illness and for disruption of carbamylglutamate access, including nutrition management strategies such as protein restriction."

NAGS-specific management guidance supports crisis planning to prevent recurrent hyperammonemia.

Target Phenotypes: Hyperammonemia ↗ Encephalopathy ↗ Vomiting ↗ Lethargy ↗ Seizures ↗

Show evidence (2 references)

PMID:38637895 SUPPORT Human Clinical

"Follow-up of patients with NAGS deficiency should include plans for illness and for disruption of carbamylglutamate access, including nutrition management strategies such as protein restriction."

Emphasizes the importance of crisis planning and supportive measures.

PMID:33179600 SUPPORT Human Clinical

"Long-term management of patients with UCDs consists of a low-protein diet, which needs to be balanced and supplemented to avoid deficiencies of essential amino acids, trace elements or vitamins and the use of nitrogen scavengers."

Supports comprehensive supportive care for long-term management.

Citrulline and arginine supplementation

Action: nutritional supplementation MAXO:0000106

Agent: citrulline ↗ L-arginine ↗

Supplementation with citrulline or arginine has been reported in some cases of NAGS deficiency to support urea cycle intermediate availability. Arginine is also a positive regulator of NAGS enzyme activity in patients with residual enzyme function.

Mechanism Target:

MODULATES Impaired arginine-mediated NAGS regulation — Arginine supplementation can support residual mammalian NAGS activation while citrulline supports downstream urea-cycle intermediate availability.

Show evidence (1 reference)

PMID:27934952 SUPPORT In Vitro

"L-arginine inhibits NAGS in bacteria, fungi, and plants and activates NAGS in mammals."

Supports L-arginine as a positive regulator of mammalian NAGS activity.

Show evidence (1 reference)

PMID:33036647 SUPPORT Human Clinical

"Supplementation with citrulline, arginine, and sodium benzoate also were reported."

Documents the use of citrulline and arginine supplementation in NAGS deficiency management.

Genetic counseling

Action: genetic counseling MAXO:0000079

Genetic counseling is essential for affected families given the autosomal recessive inheritance, recurrence risk of 25% for each subsequent pregnancy, and availability of carrier testing and prenatal diagnosis. Molecular confirmation is also critical because NAGS deficiency is clinically indistinguishable from CPS1 deficiency yet has fundamentally different therapeutic implications.

Show evidence (2 references)

PMID:38740568 SUPPORT In Vitro

"NAGSD is cured by substitutive therapy with the N-acetyl-L-glutamate analogue N-carbamyl-L-glutamate, while curative therapy of CPS1D requires liver transplantation. Since their differentiation is done genetically, it is important to ascertain the disease-causing potential of CPS1 and NAGS..."

Emphasizes the critical therapeutic implications of genetic diagnosis, supporting the role of genetic counseling.

PMID:33036647 SUPPORT Human Clinical

"N-Acetylglutamate synthase (NAGS) deficiency is an extremely rare autosomal recessive metabolic disorder"

Autosomal recessive inheritance supports the need for genetic counseling.

Carbamylglutamate therapeutic trial

Action: pharmacotherapy MAXO:0000058

Agent: carglumic acid ↗

A therapeutic trial of carbamylglutamate is recommended for any patient with unexplained hyperammonemia and a proximal urea cycle defect pattern, as it can serve both as a diagnostic tool and as definitive treatment for NAGS deficiency.

Mechanism Target:

INHIBITS Systemic hyperammonemia and glutamine diversion — Ammonia normalization after carbamylglutamate supports NAGS deficiency and treats the biochemical crisis.

Show evidence (1 reference)

PMID:33036647 SUPPORT Human Clinical

"DNA testing is the preferred method of diagnosis, although therapeutic trials to assess response of ammonia levels to carbamylglutamate may also be helpful."

Therapeutic response of ammonia levels links the trial to the systemic hyperammonemia mechanism.

Show evidence (1 reference)

PMID:33036647 SUPPORT Human Clinical

"DNA testing is the preferred method of diagnosis, although therapeutic trials to assess response of ammonia levels to carbamylglutamate may also be helpful."

Supports use of carbamylglutamate therapeutic trial for diagnosis and treatment.

🔬

Biochemical Markers

5

Plasma ammonia (INCREASED)

Context: Elevated plasma ammonia is the hallmark laboratory finding in NAGS deficiency. During acute crises, ammonia can reach extremely high levels (over 1000 micromol/L in neonatal presentations). Ammonia normalization is a key treatment response marker.

Pathograph Readouts

Readout Of Systemic hyperammonemia and glutamine diversion Positive Diagnostic

Increased plasma ammonia reports failed hepatic nitrogen disposal from the proximal urea-cycle block.

Show evidence (1 reference)

PMID:29364180 SUPPORT Human Clinical

"common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid"

The NAGS deficiency review identifies increased plasma ammonia as part of the shared proximal urea-cycle biochemical profile.

Show evidence (1 reference)

PMID:38637895 SUPPORT Human Clinical

"All patients responded well to carbamylglutamate therapy, as indicated by normalization of plasma ammonia and citrulline, as well as urine orotic acid in patients with abnormal levels at baseline."

Confirms elevated ammonia at baseline with normalization upon treatment.

Plasma glutamine (INCREASED)

Context: Elevated plasma glutamine is characteristic of proximal urea cycle defects including NAGS deficiency. Glutamine accumulates as ammonia is shunted into glutamine synthesis as an alternative detoxification pathway.

Pathograph Readouts

Readout Of Systemic hyperammonemia and glutamine diversion Positive Diagnostic

Increased plasma glutamine reports diversion of excess nitrogen into glutamine during impaired ureagenesis.

Show evidence (1 reference)

PMID:29364180 SUPPORT Human Clinical

"common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid"

The review directly supports increased plasma glutamine as part of the NAGS/CPS1-like proximal urea-cycle biochemical profile.

Show evidence (1 reference)

PMID:29364180 SUPPORT Human Clinical

"common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid"

Directly supports increased plasma glutamine in NAGS deficiency.

Plasma citrulline (DECREASED)

Context: Citrulline is typically decreased or low in proximal urea cycle defects including NAGS deficiency, reflecting reduced CPS1 activity and diminished carbamoyl phosphate production. Citrulline levels normalize with carbamylglutamate therapy.

Pathograph Readouts

Readout Of Loss of CPS1 activation and impaired ureagenesis Negative Diagnostic

Reduced plasma citrulline reports limited carbamoyl phosphate production and downstream urea-cycle flux.

Show evidence (1 reference)

PMID:29364180 SUPPORT Human Clinical

"common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid"

The review identifies reduced plasma citrulline as a biochemical readout of the proximal urea-cycle block.

Show evidence (2 references)

PMID:38637895 SUPPORT Human Clinical

"All patients responded well to carbamylglutamate therapy, as indicated by normalization of plasma ammonia and citrulline, as well as urine orotic acid in patients with abnormal levels at baseline."

Confirms abnormal (decreased) citrulline at baseline with normalization on treatment.

PMID:29364180 SUPPORT Human Clinical

"common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid"

Directly supports reduced plasma citrulline in the proximal-UCD profile of NAGS deficiency.

Urine orotic acid (DECREASED)

Context: Urine orotic acid is typically normal to low in NAGS deficiency (and CPS1 deficiency), distinguishing these proximal urea cycle defects from more distal blocks such as OTC deficiency where orotic acid is elevated. However, mild elevations have been reported in some NAGS deficiency cases.

Pathograph Readouts

Readout Of Loss of CPS1 activation and impaired ureagenesis Present Absent Diagnostic

Normal or low urinary orotic acid is the interpretable discriminator for a proximal NAGS/CPS1-like urea-cycle block rather than a distal OTC-like block.

Show evidence (1 reference)

PMID:29364180 SUPPORT Human Clinical

"common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid"

The review supports normal or low urinary orotic acid as part of the proximal urea-cycle biochemical profile.

Show evidence (2 references)

PMID:38637895 SUPPORT Human Clinical

"All patients responded well to carbamylglutamate therapy, as indicated by normalization of plasma ammonia and citrulline, as well as urine orotic acid in patients with abnormal levels at baseline."

Documents that some patients had abnormal orotic acid levels that normalized on treatment.

PMID:29364180 SUPPORT Human Clinical

"common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid"

Directly supports normal-to-low urinary orotic acid in NAGS deficiency.

N-acetylglutamate (NAG) (DECREASED)

Context: NAG is the direct product of NAGS and the essential allosteric activator of CPS1. NAG levels are reduced in NAGS deficiency, but direct measurement is not routinely available in clinical practice. The biochemical defect is bypassed by exogenous N-carbamyl-L-glutamate (carglumic acid).

Pathograph Readouts

Readout Of NAGS molecular function deficiency Negative Diagnostic

Decreased NAG reports loss of NAGS catalytic product formation, although direct NAG measurement is not routine clinically.

Show evidence (1 reference)

PMID:26068232 SUPPORT Other

"N-acetylglutamate synthase (NAGS) catalyzes the production of N-acetylglutamate (NAG) from acetyl-CoA and L-glutamate."

NAG is the direct enzymatic product of NAGS, so decreased NAG is a direct biochemical readout of NAGS function deficiency.

Show evidence (2 references)

PMID:26068232 SUPPORT Other

"N-acetylglutamate synthase (NAGS) catalyzes the production of N-acetylglutamate (NAG) from acetyl-CoA and L-glutamate."

Supports that NAGS produces NAG; its deficiency would result in decreased NAG.

PMID:38740568 SUPPORT In Vitro

"NAGS deficiency (NAGSD) and CPS1 deficiency (CPS1D) present identical phenotypes. However, they must be distinguished, because NAGSD is cured by substitutive therapy with the N-acetyl-L-glutamate analogue N-carbamyl-L-glutamate"

Confirms the NAG deficiency is the primary biochemical lesion and can be bypassed by an analogue.

{ }

Source YAML

click to show

name: N-Acetylglutamate Synthase Deficiency
category: Mendelian
creation_date: '2025-06-12T20:16:27Z'
updated_date: '2026-05-21T06:59:32Z'
classifications:
  harrisons_chapter:
  - classification_value: hereditary disease
synonyms:
- NAGS deficiency
- NAGSD
- Hyperammonemia due to N-acetylglutamate synthase deficiency
description: 'N-acetylglutamate synthase (NAGS) deficiency is an extremely rare autosomal recessive urea cycle disorder caused by biallelic pathogenic variants in the NAGS gene. NAGS catalyzes the formation of N-acetylglutamate (NAG) from acetyl-CoA and L-glutamate; NAG is the obligate allosteric activator of carbamoyl phosphate synthetase 1 (CPS1), the first enzyme of the urea cycle. Loss of NAGS activity leads to reduced NAG production, underactivation of CPS1, impaired ureagenesis, and consequent hyperammonemia. The disorder is clinically indistinguishable from CPS1 deficiency and requires molecular diagnosis. Incidence is estimated at less than one in 2,000,000 live births. Uniquely among urea cycle disorders, NAGS deficiency can be specifically treated with N-carbamyl-L-glutamate (carglumic acid), a stable NAG analogue that directly activates CPS1.

  '
disease_term:
  preferred_term: hyperammonemia due to N-acetylglutamate synthase deficiency
  term:
    id: MONDO:0009377
    label: hyperammonemia due to N-acetylglutamate synthase deficiency
parents:
- Urea Cycle Disorder
- Inborn error of metabolism
prevalence:
- notes: Extremely rare, with an estimated incidence of less than one in 2,000,000 live births. NAGS deficiency represents approximately 0.5-1% of all urea cycle disorders.
progression:
- notes: Neonatal-onset presentation is most common (58% of reported cases present before one month of age), but later-onset forms occur across a broad age spectrum including adulthood. Acute hyperammonemic crises recur during catabolic stress, illness, or interruption of therapy. Without treatment, severe neonatal hyperammonemia can cause irreversible brain damage or death. With early diagnosis and carglumic acid therapy, long-term outcomes can be favorable.
pathophysiology:
- name: NAGS molecular function deficiency
  description: 'NAGS catalyzes N-acetylglutamate (NAG) formation from acetyl-CoA and L-glutamate in the mitochondrial matrix of hepatocytes and intestinal cells. Loss of NAGS activity reduces NAG availability, creating the primary biochemical lesion in NAGS deficiency.

    '
  genes:
  - preferred_term: NAGS
    term:
      id: hgnc:17996
      label: NAGS
  molecular_functions:
  - preferred_term: N-acetylglutamate synthase activity
    term:
      id: GO:0004042
      label: L-glutamate N-acetyltransferase activity, acting on acetyl-CoA as donor
    modifier: DECREASED
  cell_types:
  - preferred_term: hepatocyte
    term:
      id: CL:0000182
      label: hepatocyte
  locations:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  downstream:
  - target: N-acetylglutamate (NAG)
    description: Loss of NAGS enzyme activity lowers production of N-acetylglutamate, the endogenous CPS1 activator.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:26068232
      reference_title: "The N-Acetylglutamate Synthase Family: Structures, Function and Mechanisms."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: N-acetylglutamate synthase (NAGS) catalyzes the production of N-acetylglutamate (NAG) from acetyl-CoA and L-glutamate.
      explanation: Directly supports NAG as the product of NAGS and therefore the depleted metabolite when NAGS function is deficient.
  - target: Loss of CPS1 activation and impaired ureagenesis
    description: NAG depletion prevents normal allosteric activation of CPS1.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:38740568
      reference_title: "Use of pure recombinant human enzymes to assess the disease-causing potential of missense mutations in urea cycle disorders, applied to N-acetylglutamate synthase deficiency."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: N-acetylglutamate synthase (NAGS) makes acetylglutamate, the essential activator of the first, regulatory enzyme of the urea cycle, carbamoyl phosphate synthetase 1 (CPS1).
      explanation: Directly links NAGS product formation to CPS1 activation.
  evidence:
  - reference: PMID:26068232
    reference_title: "The N-Acetylglutamate Synthase Family: Structures, Function and Mechanisms."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: N-acetylglutamate synthase (NAGS) catalyzes the production of N-acetylglutamate (NAG) from acetyl-CoA and L-glutamate.
    explanation: Directly supports NAGS as the enzyme responsible for NAG production.
  - reference: PMID:38740568
    reference_title: "Use of pure recombinant human enzymes to assess the disease-causing potential of missense mutations in urea cycle disorders, applied to N-acetylglutamate synthase deficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: N-acetylglutamate synthase (NAGS) makes acetylglutamate, the essential activator of the first, regulatory enzyme of the urea cycle, carbamoyl phosphate synthetase 1 (CPS1).
    explanation: Supports the mechanistic dependency of CPS1 activation on NAG production by NAGS.
- name: Loss of CPS1 activation and impaired ureagenesis
  description: 'NAG is the obligate allosteric activator of CPS1. When NAG is deficient, CPS1 remains underactivated, reducing carbamoyl phosphate formation and impairing proximal urea cycle flux.

    '
  biological_processes:
  - preferred_term: urea cycle
    term:
      id: GO:0000050
      label: urea cycle
  chemical_entities:
  - preferred_term: ammonia
    term:
      id: CHEBI:16134
      label: ammonia
    modifier: INCREASED
  - preferred_term: citrulline
    term:
      id: CHEBI:18211
      label: citrulline
    modifier: DECREASED
  locations:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  downstream:
  - target: Systemic hyperammonemia and glutamine diversion
    description: Impaired ureagenesis prevents hepatic ammonia disposal, producing the proximal-UCD biochemical profile.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29364180
      reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Clinically and biochemically, NAGSD is indistinguishable from CPS1 deficiency (CPS1D), and common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid
      explanation: Defines the biochemical pattern produced by the NAG-CPS1 proximal urea-cycle block.
  evidence:
  - reference: PMID:27570737
    reference_title: "N-acetylglutamate synthase deficiency: Novel mutation associated with neonatal presentation and literature review of molecular and phenotypic spectra."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Carbamoylphosphate synthetase 1 (CPS1), the first and rate-limiting enzyme of urea cycle, is activated by N-acetylglutamate (NAG), and thus N-acetylglutamate synthase (NAGS) is an essential part of the urea cycle.
    explanation: Directly supports the NAG-CPS1 dependency and proximal urea cycle block when NAGS is deficient.
  - reference: PMID:38637895
    reference_title: "The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperammonemic crises can be avoided in individuals with NAGS deficiency by the administration of carbamylglutamate (also known as carglumic acid), which activates carbamoyl phosphatase synthetase 1 (CPS1).
    explanation: Clinical response to CPS1 activation supports CPS1 underactivation as a causal step.
- name: Systemic hyperammonemia and glutamine diversion
  description: 'Reduced NAG-dependent CPS1 activation impairs hepatic nitrogen disposal. Ammonia and glutamine rise, citrulline falls, and urinary orotic acid remains normal to low, creating the systemic biochemical state that drives acute decompensation.

    '
  biological_processes:
  - preferred_term: urea cycle
    term:
      id: GO:0000050
      label: urea cycle
  chemical_entities:
  - preferred_term: ammonia
    term:
      id: CHEBI:16134
      label: ammonia
    modifier: INCREASED
  - preferred_term: glutamine
    term:
      id: CHEBI:28300
      label: glutamine
    modifier: INCREASED
  - preferred_term: citrulline
    term:
      id: CHEBI:18211
      label: citrulline
    modifier: DECREASED
  locations:
  - preferred_term: liver
    term:
      id: UBERON:0002107
      label: liver
  evidence:
  - reference: PMID:29364180
    reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Clinically and biochemically, NAGSD is indistinguishable from CPS1 deficiency (CPS1D), and common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid
    explanation: Supports the systemic proximal-UCD biochemical profile caused by NAGS deficiency.
  downstream:
  - target: Plasma ammonia
    description: Failed hepatic ureagenesis manifests biochemically as increased circulating ammonia.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29364180
      reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid
      explanation: Directly supports increased plasma ammonia in NAGS deficiency.
  - target: Plasma glutamine
    description: Excess nitrogen is diverted into glutamine, increasing plasma glutamine.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:29364180
      reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid
      explanation: Directly supports increased plasma glutamine in the proximal-UCD biochemical profile.
  - target: Plasma citrulline
    description: Reduced CPS1 activation limits carbamoyl phosphate availability for downstream citrulline synthesis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:29364180
      reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid
      explanation: Directly supports low plasma citrulline in NAGS deficiency.
  - target: Urine orotic acid
    description: The proximal urea-cycle block leaves urinary orotic acid normal to low, distinguishing NAGS/CPS1 deficiency from OTC deficiency.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:29364180
      reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid
      explanation: Directly supports normal-to-low urinary orotic acid as part of the proximal-UCD pattern.
  - target: Hyperammonemia
    description: Systemic ammonia accumulation is the defining clinical biochemical phenotype.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33036647
      reference_title: "Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: N-Acetylglutamate synthase (NAGS) deficiency is an extremely rare autosomal recessive metabolic disorder affecting the urea cycle, leading to episodes of hyperammonemia which can cause significant morbidity and mortality.
      explanation: Directly identifies hyperammonemia as the downstream clinical manifestation of NAGS deficiency.
  - target: Vomiting
    description: Acute hyperammonemic decompensation can present with nausea and vomiting.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29364180
      reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: During the hospitalization, hyperammonemia associated with confusion, psychomotor agitation (i.e., echolalia and motor stereotypies), nausea, and vomiting was detected several times, mainly in the evening.
      explanation: This NAGS deficiency case directly links hyperammonemia episodes with nausea and vomiting.
  - target: Lethargy
    description: Hyperammonemic NAGS deficiency can present with reduced alertness and lethargy.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29364180
      reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Adult patients are very rare and often unrecognized. They may present with a self-selected low protein diet, headaches, vomiting, lethargy, behavioural changes, confusion, episodes of altered consciousness, and hyperammonemic encephalopathy
      explanation: The NAGS deficiency review lists lethargy among late-onset clinical manifestations linked to hyperammonemic encephalopathy.
  - target: Headache
    description: Late-onset NAGS deficiency can manifest with recurrent headaches driven by hyperammonemia and/or hypoargininemia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:29364180
      reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Headaches in UCD patients are often recurrent, associated with behavioural symptoms, nausea and vomiting, or a self-selected low protein diet, and are due to hyperammonemia and/or hypoargininemia.
      explanation: The NAGS case review directly links recurrent UCD headaches to hyperammonemia and/or hypoargininemia.
  - target: Respiratory alkalosis
    description: Neonatal urea-cycle hyperammonemia can first present with tachypnea and respiratory alkalosis.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33113778
      reference_title: "Irritability, Poor Feeding and Respiratory Alkalosis in Newborns: Think about Metabolic Emergencies. A Brief Summary of Hyperammonemia Management."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: We report a series of three newborns presenting irritability, poor feeding and tachypnea. Their first gas analysis revealed respiratory alkalosis. Hyperammonemia was confirmed, and three different enzymatic blocks in the urea cycle were diagnosed.
      explanation: Human neonatal UCD cases show respiratory alkalosis as an early presentation of confirmed hyperammonemia.
  - target: Hyperammonemic astrocyte stress and glutamine accumulation
    description: Circulating ammonia crosses into the CNS and is converted to glutamine in astrocytes.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33409766
      reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Ammonia passes into the circulation and crosses the blood–brain barrier. The ammonia will exert a direct toxic effect on the neurotransmission responsible for part of the neurological symptomatology.
      explanation: UCD pathophysiology review links circulating ammonia to CNS neurotoxicity.
- name: Impaired arginine-mediated NAGS regulation
  description: 'NAGS activity is allosterically regulated by L-arginine, which increases enzyme activity 2-5-fold under physiological conditions. Many disease-causing NAGS variants show loss of arginine activation as their primary mechanistic defect. Hampered NAGS activation by arginine has emerged as a paramount causative factor of NAGS deficiency.

    '
  biological_processes:
  - preferred_term: urea cycle
    term:
      id: GO:0000050
      label: urea cycle
  - preferred_term: positive regulation of catalytic activity
    term:
      id: GO:0043085
      label: positive regulation of catalytic activity
  evidence:
  - reference: PMID:27934952
    reference_title: "Effect of arginine on oligomerization and stability of N-acetylglutamate synthase."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: L-arginine inhibits NAGS in bacteria, fungi, and plants and activates NAGS in mammals.
    explanation: Confirms that L-arginine is a positive regulator of mammalian NAGS activity.
  downstream:
  - target: Loss of CPS1 activation and impaired ureagenesis
    description: Loss of arginine-mediated NAGS activation further reduces NAG-dependent CPS1 activation.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:27934952
      reference_title: "Effect of arginine on oligomerization and stability of N-acetylglutamate synthase."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: L-arginine inhibits NAGS in bacteria, fungi, and plants and activates NAGS in mammals.
      explanation: Loss of mammalian arginine activation reduces NAGS-mediated production of the CPS1 activator.
- name: Hyperammonemic astrocyte stress and glutamine accumulation
  description: 'Hyperammonemia drives encephalopathy and astrocyte stress in the brain. Ammonia detoxification in astrocytes increases glutamine production, creating intracellular osmotic burden and vulnerability to swelling.

    '
  biological_processes:
  - preferred_term: glutamine biosynthetic process
    term:
      id: GO:1901704
      label: L-glutamine biosynthetic process
  chemical_entities:
  - preferred_term: ammonia
    term:
      id: CHEBI:16134
      label: ammonia
    modifier: INCREASED
  - preferred_term: glutamine
    term:
      id: CHEBI:28300
      label: glutamine
    modifier: INCREASED
  cell_types:
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  downstream:
  - target: Seizures
    description: Hyperammonemic CNS stress can cause epileptiform activity and seizures during decompensation.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:29364180
      reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: EEG showed abnormalities which were consistent with non-convulsive status epilepticus.
      explanation: This NAGS deficiency case documents seizure-spectrum EEG abnormalities during a hyperammonemic crisis.
  - target: Cytotoxic cerebral edema and intracranial hypertension
    description: Astrocytic osmotic stress can progress to cerebral edema and life-threatening intracranial complications.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33409766
      reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Ammonia diffuses freely across the blood–brain barrier and is converted with alanine to glutamine by glutamine synthase. Glutamine is the main intracellular osmole of the brain. Its accumulation causes the swelling of astrocytes during hyperammonemia
      explanation: Mechanistic UCD review supports the ammonia-to-astrocyte-glutamine osmotic injury step.
  - target: Encephalopathy
    description: Astrocyte ammonia/glutamine stress produces acute hyperammonemic encephalopathy.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33179600
      reference_title: "Primary hyperammonaemia: Current diagnostic and therapeutic strategies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Newborns who are often affected by hyper-ammonaemic encephalopathy carry a potential risk of severe brain damage, which may lead to death.
      explanation: Clinical review directly supports hyperammonemic encephalopathy as the neurologic consequence.
  evidence:
  - reference: PMID:33179600
    reference_title: "Primary hyperammonaemia: Current diagnostic and therapeutic strategies."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: Newborns who are often affected by hyper-ammonaemic encephalopathy carry a potential risk of severe brain damage, which may lead to death.
    explanation: Supports severe hyperammonemic encephalopathy as the upstream neurotoxic state.
- name: Cytotoxic cerebral edema and intracranial hypertension
  description: 'In severe crises, ammonia-mediated brain injury progresses to cerebral edema, intracranial hypertension, and risk of herniation, coma, and death.

    '
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  downstream:
  - target: Cerebral edema
    description: Intracranial hypertension and brain swelling manifest clinically as cerebral edema.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:33409766
      reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: emergent hemodialysis is mandatory before referral to a reference center if ammonia levels are above 200 µmol/l as the risk of cerebral edema is then above 55%.
      explanation: Human UCD review links severe hyperammonemia to high cerebral edema risk.
  - target: Coma
    description: Raised intracranial pressure from severe ammonia neurotoxicity can progress to coma.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33409766
      reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Intra cranial hypertension appears inducing coma, cerebral engagement and death of the patient.
      explanation: Mechanistic UCD review links intracranial hypertension to coma and death.
  - target: Intellectual disability
    description: Severe or recurrent hyperammonemic brain injury can leave lasting cognitive sequelae.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:33179600
      reference_title: "Primary hyperammonaemia: Current diagnostic and therapeutic strategies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Newborns who are often affected by hyper-ammonaemic encephalopathy carry a potential risk of severe brain damage, which may lead to death.
      explanation: Severe hyperammonemic encephalopathy provides the brain-injury mechanism underlying long-term cognitive sequelae.
  evidence:
  - reference: PMID:33409766
    reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Awareness of urea cycle disorders in adults intensive care units can optimize early management and accordingly dramatically improve prognosis. By preventing hyperammonemia to induce brain edema and herniation leading to death.
    explanation: Directly supports progression from hyperammonemia to cerebral edema and herniation.
  - reference: PMID:33179600
    reference_title: "Primary hyperammonaemia: Current diagnostic and therapeutic strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Newborns who are often affected by hyper-ammonaemic encephalopathy carry a potential risk of severe brain damage, which may lead to death.
    explanation: Supports severe neurological outcomes in untreated neonatal hyperammonemic crises.
- name: Variant-specific biochemical mechanisms of NAGS dysfunction
  description: 'Functional characterization of 23 patient-derived NAGS missense variants using stabilized recombinant human enzyme has identified multiple mechanistic classes of pathogenicity including loss of arginine activation, increased Km for glutamate, active site inactivation, decreased thermal stability, and protein misfolding. This approach outperforms bacterial surrogate enzymes and in silico prediction tools for assessing pathogenicity and guiding therapeutic decisions.

    '
  evidence:
  - reference: PMID:38740568
    reference_title: "Use of pure recombinant human enzymes to assess the disease-causing potential of missense mutations in urea cycle disorders, applied to N-acetylglutamate synthase deficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Our present approach outperforms experimental in vitro use of bacterial NAGS or in silico utilization of prediction servers (including AlphaMissense), illustrating with HuNAGS the value for UCDs of using recombinant enzymes for assessing disease-causation and molecular pathogenesis, and for therapeutic guidance.
    explanation: Validates the recombinant human enzyme approach for functional variant characterization.
  - reference: PMID:38740568
    reference_title: "Use of pure recombinant human enzymes to assess the disease-causing potential of missense mutations in urea cycle disorders, applied to N-acetylglutamate synthase deficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: For all but one change, disease causation was accounted by the enzymatic alterations identified, including, depending on the variant, loss of arginine activation, increased Km Glutamate, active site inactivation, decreased thermal stability, and protein misfolding.
    explanation: Defines the variant-level enzyme mechanisms that feed into NAGS dysfunction.
  downstream:
  - target: NAGS molecular function deficiency
    description: Patient-derived missense variants reduce NAGS enzyme function by multiple biochemical mechanisms.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:38740568
      reference_title: "Use of pure recombinant human enzymes to assess the disease-causing potential of missense mutations in urea cycle disorders, applied to N-acetylglutamate synthase deficiency."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: For all but one change, disease causation was accounted by the enzymatic alterations identified, including, depending on the variant, loss of arginine activation, increased Km Glutamate, active site inactivation, decreased thermal stability, and protein misfolding.
      explanation: Variant-level enzyme defects directly explain the upstream NAGS molecular function deficiency.
  - target: Impaired arginine-mediated NAGS regulation
    description: Loss of arginine activation is one functional class of pathogenic NAGS variant.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:38740568
      reference_title: "Use of pure recombinant human enzymes to assess the disease-causing potential of missense mutations in urea cycle disorders, applied to N-acetylglutamate synthase deficiency."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: For all but one change, disease causation was accounted by the enzymatic alterations identified, including, depending on the variant, loss of arginine activation, increased Km Glutamate, active site inactivation, decreased thermal stability, and protein misfolding.
      explanation: The recombinant human enzyme assay identifies loss of arginine activation as a pathogenic NAGS mechanism.
phenotypes:
- name: Hyperammonemia
  frequency: VERY_FREQUENT
  description: 'Elevated plasma ammonia is the cardinal biochemical and clinical feature of NAGS deficiency, resulting from impaired urea cycle flux. Ammonia levels can be extremely elevated during acute crises, with values exceeding 1000 micromol/L reported in neonatal presentations.

    '
  phenotype_term:
    preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  evidence:
  - reference: PMID:33036647
    reference_title: "Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: N-Acetylglutamate synthase (NAGS) deficiency is an extremely rare autosomal recessive metabolic disorder affecting the urea cycle, leading to episodes of hyperammonemia which can cause significant morbidity and mortality.
    explanation: Directly identifies hyperammonemia as the defining feature of NAGS deficiency.
  - reference: PMID:38637895
    reference_title: "The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Hyperammonemic crises can be avoided in individuals with NAGS deficiency by the administration of carbamylglutamate (also known as carglumic acid), which activates carbamoyl phosphatase synthetase 1 (CPS1).
    explanation: Confirms hyperammonemic crises as the key clinical problem in NAGS deficiency.
- name: Encephalopathy
  frequency: VERY_FREQUENT
  description: 'Hyperammonemic encephalopathy is the most common and dangerous neurological manifestation, presenting with progressive lethargy, altered consciousness, and coma. It results from ammonia-driven astrocyte swelling and cerebral edema and carries significant risk of permanent brain damage or death.

    '
  phenotype_term:
    preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  evidence:
  - reference: PMID:33179600
    reference_title: "Primary hyperammonaemia: Current diagnostic and therapeutic strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Newborns who are often affected by hyper-ammonaemic encephalopathy carry a potential risk of severe brain damage, which may lead to death.
    explanation: Directly supports hyperammonemic encephalopathy as a common severe presentation of UCDs.
- name: Vomiting
  frequency: FREQUENT
  description: 'Recurrent vomiting is a common presenting symptom, particularly during metabolic decompensation and acute hyperammonemic crises.

    '
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  evidence:
  - reference: PMID:29364180
    reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: headaches had been present since puberty (3-4 days a week) and were often accompanied by nausea, vomiting, or behavioural changes.
    explanation: Documents vomiting as a recurrent symptom in a late-onset NAGS deficiency case.
- name: Lethargy
  frequency: FREQUENT
  description: 'Decreased alertness and progressive lethargy are early signs of hyperammonemic crisis and can rapidly progress to coma without treatment.

    '
  phenotype_term:
    preferred_term: Lethargy
    term:
      id: HP:0001254
      label: Lethargy
  evidence:
  - reference: PMID:33179600
    reference_title: "Primary hyperammonaemia: Current diagnostic and therapeutic strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Outside the neonatal period, symptoms are very unspecific but most often neurological (with wide variability), psychiatric and/or gastrointestinal.
    explanation: Supports neurological symptoms including altered consciousness in UCDs.
- name: Seizures
  frequency: OCCASIONAL
  description: 'Seizures may occur during acute hyperammonemic episodes, particularly in the neonatal period or during severe metabolic decompensation. One reported patient experienced seizures that limited the caregiver''s ability to administer medication, leading to further hyperammonemia.

    '
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:38637895
    reference_title: "The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: once due to seizure activity limiting the family's ability to administer carbamylglutamate.
    explanation: Documents seizure activity in a patient with NAGS deficiency.
- name: Intellectual disability
  frequency: OCCASIONAL
  description: 'Intellectual disability can result from brain damage sustained during hyperammonemic crises, especially in neonatal-onset cases with delayed diagnosis or treatment.

    '
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:38637895
    reference_title: "The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: One patient experienced two episodes of hyperammonemia that resulted in poor long-term outcomes.
    explanation: Documents poor long-term outcomes from hyperammonemic episodes in NAGS deficiency.
- name: Failure to thrive
  frequency: FREQUENT
  description: >-
    Poor growth and feeding difficulties are common in neonatal-onset NAGS deficiency, particularly
    before diagnosis and initiation of appropriate therapy.
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  notes: >-
    Failure to thrive is well-documented in neonatal-onset UCD presentations. The NAGS systematic review
    (PMID:33036647, 98 cases) describes the clinical spectrum including 57 neonatal cases, but the abstract
    does not specifically quantify FTT frequency.
- name: Headache
  frequency: OCCASIONAL
  description: 'Recurrent headaches may be the presenting or sole symptom in late-onset NAGS deficiency. One paradigmatic adult case presented with headaches occurring 3-4 days per week since puberty, often accompanied by nausea, vomiting, or behavioral changes.

    '
  phenotype_term:
    preferred_term: Headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: PMID:29364180
    reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The manuscript underlies that headache may be the presenting symptom of UCDs and provides clues for the rapid diagnosis and treatment of late-onset NAGSD.
    explanation: Highlights headache as a diagnostically important symptom in late-onset NAGS deficiency.
- name: Cerebral edema
  frequency: OCCASIONAL
  description: 'Cerebral edema results from astrocytic glutamine accumulation during severe hyperammonemia and can progress to intracranial hypertension and brain herniation if untreated.

    '
  phenotype_term:
    preferred_term: Cerebral edema
    term:
      id: HP:0002181
      label: Cerebral edema
  evidence:
  - reference: PMID:33409766
    reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: By preventing hyperammonemia to induce brain edema and herniation leading to death.
    explanation: Directly supports cerebral edema as a consequence of hyperammonemia in UCDs.
- name: Coma
  frequency: OCCASIONAL
  description: 'Hyperammonemic coma can occur during severe acute decompensation, particularly in neonatal-onset cases. Three episodes of altered consciousness were documented before the diagnosis of NAGS deficiency in one adult case.

    '
  phenotype_term:
    preferred_term: Coma
    term:
      id: HP:0001259
      label: Coma
  evidence:
  - reference: PMID:29364180
    reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Despite three previous episodes of altered consciousness, ammonia was measured for the first time at 52 years and levels were increased.
    explanation: Documents recurrent episodes of altered consciousness before NAGS deficiency diagnosis.
- name: Respiratory alkalosis
  frequency: OCCASIONAL
  description: >-
    Hyperventilation and respiratory alkalosis can occur during hyperammonemic episodes as a
    compensatory response to metabolic disturbance.
  phenotype_term:
    preferred_term: Respiratory alkalosis
    term:
      id: HP:0001950
      label: Respiratory alkalosis
  notes: >-
    Respiratory alkalosis from hyperventilation is a recognized feature of acute hyperammonemia
    in urea cycle disorders generally but specific frequency data for NAGS deficiency are limited.
  evidence:
  - reference: PMID:33113778
    reference_title: "Irritability, Poor Feeding and Respiratory Alkalosis in Newborns: Think about Metabolic Emergencies. A Brief Summary of Hyperammonemia Management."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We report a series of three newborns presenting irritability, poor feeding and tachypnea. Their first gas analysis revealed respiratory alkalosis. Hyperammonemia was confirmed, and three different enzymatic blocks in the urea cycle were diagnosed.
    explanation: Human neonatal UCD cases support respiratory alkalosis as an early hyperammonemia presentation.
biochemical:
- name: Plasma ammonia
  presence: INCREASED
  context: 'Elevated plasma ammonia is the hallmark laboratory finding in NAGS deficiency. During acute crises, ammonia can reach extremely high levels (over 1000 micromol/L in neonatal presentations). Ammonia normalization is a key treatment response marker.

    '
  biomarker_term:
    preferred_term: ammonium
    term:
      id: CHEBI:28938
      label: ammonium
  readouts:
  - target: Systemic hyperammonemia and glutamine diversion
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Increased plasma ammonia reports failed hepatic nitrogen disposal from the proximal urea-cycle block.
    evidence:
    - reference: PMID:29364180
      reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid
      explanation: The NAGS deficiency review identifies increased plasma ammonia as part of the shared proximal urea-cycle biochemical profile.
  evidence:
  - reference: PMID:38637895
    reference_title: "The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: All patients responded well to carbamylglutamate therapy, as indicated by normalization of plasma ammonia and citrulline, as well as urine orotic acid in patients with abnormal levels at baseline.
    explanation: Confirms elevated ammonia at baseline with normalization upon treatment.
- name: Plasma glutamine
  presence: INCREASED
  context: >-
    Elevated plasma glutamine is characteristic of proximal urea cycle defects including NAGS deficiency.
    Glutamine accumulates as ammonia is shunted into glutamine synthesis as an alternative detoxification
    pathway.
  biomarker_term:
    preferred_term: glutamine
    term:
      id: CHEBI:28300
      label: glutamine
  readouts:
  - target: Systemic hyperammonemia and glutamine diversion
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Increased plasma glutamine reports diversion of excess nitrogen into glutamine during impaired ureagenesis.
    evidence:
    - reference: PMID:29364180
      reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid
      explanation: The review directly supports increased plasma glutamine as part of the NAGS/CPS1-like proximal urea-cycle biochemical profile.
  notes: >-
    Elevated plasma glutamine is a well-established biochemical feature of proximal urea cycle defects
    (NAGS and CPS1 deficiency), reflecting ammonia diversion into glutamine synthesis. The available
    NAGS case series abstracts (PMID:38637895, PMID:27570737) do not explicitly mention glutamine
    levels, though it is a standard finding in proximal UCD biochemical workup.
  evidence:
  - reference: PMID:29364180
    reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid
    explanation: Directly supports increased plasma glutamine in NAGS deficiency.
- name: Plasma citrulline
  presence: DECREASED
  frequency: FREQUENT
  context: 'Citrulline is typically decreased or low in proximal urea cycle defects including NAGS deficiency, reflecting reduced CPS1 activity and diminished carbamoyl phosphate production. Citrulline levels normalize with carbamylglutamate therapy.

    '
  biomarker_term:
    preferred_term: citrulline
    term:
      id: CHEBI:18211
      label: citrulline
  readouts:
  - target: Loss of CPS1 activation and impaired ureagenesis
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Reduced plasma citrulline reports limited carbamoyl phosphate production and downstream urea-cycle flux.
    evidence:
    - reference: PMID:29364180
      reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid
      explanation: The review identifies reduced plasma citrulline as a biochemical readout of the proximal urea-cycle block.
  evidence:
  - reference: PMID:38637895
    reference_title: "The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: All patients responded well to carbamylglutamate therapy, as indicated by normalization of plasma ammonia and citrulline, as well as urine orotic acid in patients with abnormal levels at baseline.
    explanation: Confirms abnormal (decreased) citrulline at baseline with normalization on treatment.
  - reference: PMID:29364180
    reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid
    explanation: Directly supports reduced plasma citrulline in the proximal-UCD profile of NAGS deficiency.
- name: Urine orotic acid
  presence: DECREASED
  frequency: FREQUENT
  context: 'Urine orotic acid is typically normal to low in NAGS deficiency (and CPS1 deficiency), distinguishing these proximal urea cycle defects from more distal blocks such as OTC deficiency where orotic acid is elevated. However, mild elevations have been reported in some NAGS deficiency cases.

    '
  notes: 'Normal or low urine orotic acid helps differentiate NAGS/CPS1 deficiency from OTC deficiency, but is not a fully reliable discriminator.

    '
  biomarker_term:
    preferred_term: orotic acid
    term:
      id: CHEBI:16742
      label: orotic acid
  readouts:
  - target: Loss of CPS1 activation and impaired ureagenesis
    relationship: READOUT_OF
    direction: PRESENT_ABSENT
    endpoint_context: DIAGNOSTIC
    interpretation: Normal or low urinary orotic acid is the interpretable discriminator for a proximal NAGS/CPS1-like urea-cycle block rather than a distal OTC-like block.
    evidence:
    - reference: PMID:29364180
      reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid
      explanation: The review supports normal or low urinary orotic acid as part of the proximal urea-cycle biochemical profile.
  evidence:
  - reference: PMID:38637895
    reference_title: "The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: All patients responded well to carbamylglutamate therapy, as indicated by normalization of plasma ammonia and citrulline, as well as urine orotic acid in patients with abnormal levels at baseline.
    explanation: Documents that some patients had abnormal orotic acid levels that normalized on treatment.
  - reference: PMID:29364180
    reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: common biochemical features include increased amounts of plasma ammonia and glutamine, reduced plasma citrulline, and normal or low levels of urinary orotic acid
    explanation: Directly supports normal-to-low urinary orotic acid in NAGS deficiency.
- name: N-acetylglutamate (NAG)
  presence: DECREASED
  context: 'NAG is the direct product of NAGS and the essential allosteric activator of CPS1. NAG levels are reduced in NAGS deficiency, but direct measurement is not routinely available in clinical practice. The biochemical defect is bypassed by exogenous N-carbamyl-L-glutamate (carglumic acid).

    '
  biomarker_term:
    preferred_term: N-acetyl-L-glutamate
    term:
      id: CHEBI:44337
      label: N-acetyl-L-glutamate(2-)
  readouts:
  - target: NAGS molecular function deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Decreased NAG reports loss of NAGS catalytic product formation, although direct NAG measurement is not routine clinically.
    evidence:
    - reference: PMID:26068232
      reference_title: "The N-Acetylglutamate Synthase Family: Structures, Function and Mechanisms."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: N-acetylglutamate synthase (NAGS) catalyzes the production of N-acetylglutamate (NAG) from acetyl-CoA and L-glutamate.
      explanation: NAG is the direct enzymatic product of NAGS, so decreased NAG is a direct biochemical readout of NAGS function deficiency.
  evidence:
  - reference: PMID:26068232
    reference_title: "The N-Acetylglutamate Synthase Family: Structures, Function and Mechanisms."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: N-acetylglutamate synthase (NAGS) catalyzes the production of N-acetylglutamate (NAG) from acetyl-CoA and L-glutamate.
    explanation: Supports that NAGS produces NAG; its deficiency would result in decreased NAG.
  - reference: PMID:38740568
    reference_title: "Use of pure recombinant human enzymes to assess the disease-causing potential of missense mutations in urea cycle disorders, applied to N-acetylglutamate synthase deficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: NAGS deficiency (NAGSD) and CPS1 deficiency (CPS1D) present identical phenotypes. However, they must be distinguished, because NAGSD is cured by substitutive therapy with the N-acetyl-L-glutamate analogue N-carbamyl-L-glutamate
    explanation: Confirms the NAG deficiency is the primary biochemical lesion and can be bypassed by an analogue.
genetic:
- name: NAGS pathogenic variants
  gene_term:
    preferred_term: NAGS
    term:
      id: hgnc:17996
      label: NAGS
  inheritance:
  - name: Autosomal recessive
    evidence:
    - reference: PMID:33036647
      reference_title: "Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: N-Acetylglutamate synthase (NAGS) deficiency is an extremely rare autosomal recessive metabolic disorder affecting the urea cycle
      explanation: Directly confirms autosomal recessive inheritance.
    - reference: PMID:38637895
      reference_title: "The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The autosomal recessive disorder N-acetylglutamate synthase (NAGS) deficiency is the rarest defect of the urea cycle
      explanation: Confirms autosomal recessive inheritance in a 2024 case series.
  variants:
  - name: NAGS - c.1097-2A>T splice-site variant
    description: 'Novel homozygous splice-site mutation found in an infant with neonatal hyperammonemia who had rapid response to N-carbamylglutamate treatment.

      '
    evidence:
    - reference: PMID:27570737
      reference_title: "N-acetylglutamate synthase deficiency: Novel mutation associated with neonatal presentation and literature review of molecular and phenotypic spectra."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: She was found to have a novel homozygous splice-site mutation, c.1097-2A>T, in the NAGS gene.
      explanation: Documents a specific pathogenic variant identified in a neonatal NAGS deficiency case.
  - name: NAGS - c.344C>T (p.Ala115Val) missense variant
    description: 'Homozygous missense variant identified in a late-onset adult case presenting with recurrent headaches. Bioinformatic analysis suggested that the mutation could affect the arginine-binding site, resulting in poor enzyme activation and late-onset presentation.

      '
    evidence:
    - reference: PMID:29364180
      reference_title: "Late-Onset N-Acetylglutamate Synthase Deficiency: Report of a Paradigmatic Adult Case Presenting with Headaches and Review of the Literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Identification of the new homozygous c.344C>T (p.Ala115Val) NAGS variant allowed the definite diagnosis of NAGSD.
      explanation: Directly supports the c.344C>T (p.Ala115Val) variant assignment in a late-onset adult case.
  - name: NAGS - Multiple nonsynonymous variants characterized by recombinant enzyme assay
    description: 'Twenty-three nonsynonymous single-base changes from NAGS deficiency patients were functionally characterized using stabilized recombinant human NAGS. Pathogenic mechanisms identified include loss of arginine activation, increased Km for glutamate, active site inactivation, decreased thermal stability, and protein misfolding.

      '
  features: 'Biallelic pathogenic variants in NAGS cause NAGS deficiency. NAGS is located on chromosome 17q21.31 and encodes the mitochondrial enzyme N-acetylglutamate synthase. The enzyme is localized to the mitochondrial matrix of hepatocytes and intestinal cells. Over 60 pathogenic variants have been reported across multiple domains of the protein. Both neonatal-onset (severe) and late-onset (milder) phenotypes have been described, with genotype-phenotype correlation partly dependent on the specific biochemical mechanism affected by each variant.

    '
  evidence:
  - reference: PMID:33036647
    reference_title: "Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: In total, 98 cases of NAGS deficiency from 79 families, in 48 articles or abstracts were identified.
    explanation: Documents the breadth of reported NAGS deficiency cases and families with diverse variants.
  - reference: PMID:38740568
    reference_title: "Use of pure recombinant human enzymes to assess the disease-causing potential of missense mutations in urea cycle disorders, applied to N-acetylglutamate synthase deficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: NAGSD is cured by substitutive therapy with the N-acetyl-L-glutamate analogue N-carbamyl-L-glutamate, while curative therapy of CPS1D requires liver transplantation. Since their differentiation is done genetically, it is important to ascertain the disease-causing potential of CPS1 and NAGS genetic variants.
    explanation: Emphasizes the critical importance of genetic characterization for differentiating NAGS deficiency from CPS1 deficiency.
  - reference: CGGV:assertion_33dcead1-e3d9-4427-98fd-05a655c8c213-2019-07-26T160000.000Z
    reference_title: "NAGS / hyperammonemia due to N-acetylglutamate synthase deficiency (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "NAGS | HGNC:17996 | hyperammonemia due to N-acetylglutamate synthase deficiency | MONDO:0009377 | AR | Definitive"
    explanation: ClinGen classifies the NAGS-hyperammonemia due to N-acetylglutamate synthase deficiency gene-disease relationship as definitive with autosomal recessive inheritance.
treatments:
- name: Carglumic acid (N-carbamyl-L-glutamate)
  description: 'Carglumic acid is a synthetic stable analogue of N-acetylglutamate that directly activates CPS1, bypassing deficient NAGS and restoring urea cycle flux. It is the specific disease-modifying therapy for NAGS deficiency and the only urea cycle disorder that can be cured by substitutive drug therapy. All patients in the 2024 case series responded well to carbamylglutamate therapy, with normalization of ammonia, citrulline, and orotic acid.

    '
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: carglumic acid
      term:
        id: CHEBI:71028
        label: carglumic acid
  target_mechanisms:
  - target: Loss of CPS1 activation and impaired ureagenesis
    treatment_effect: RESTORES
    description: Carglumic acid is a stable NAG analogue that activates CPS1 despite deficient NAGS activity.
    evidence:
    - reference: PMID:27570737
      reference_title: "N-acetylglutamate synthase deficiency: Novel mutation associated with neonatal presentation and literature review of molecular and phenotypic spectra."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Although NAGS deficiency is the rarest urea cycle disorder, it is the only one that can be specifically and effectively treated by a drug, N-carbamylglutamate, a stable structural analogous of NAG that activates CPS1.
      explanation: Directly supports carglumic acid as a CPS1-activating NAG analogue.
  - target: Systemic hyperammonemia and glutamine diversion
    treatment_effect: INHIBITS
    description: Restored CPS1 activation improves urea-cycle flux and normalizes hyperammonemia-associated biochemical abnormalities.
    evidence:
    - reference: PMID:38637895
      reference_title: "The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: All patients responded well to carbamylglutamate therapy, as indicated by normalization of plasma ammonia and citrulline, as well as urine orotic acid in patients with abnormal levels at baseline.
      explanation: Clinical response shows inhibition of the systemic biochemical decompensation state.
  evidence:
  - reference: PMID:38637895
    reference_title: "The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: All patients responded well to carbamylglutamate therapy, as indicated by normalization of plasma ammonia and citrulline, as well as urine orotic acid in patients with abnormal levels at baseline.
    explanation: Directly demonstrates efficacy of carbamylglutamate in normalizing biochemical parameters.
  - reference: PMID:27570737
    reference_title: "N-acetylglutamate synthase deficiency: Novel mutation associated with neonatal presentation and literature review of molecular and phenotypic spectra."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Although NAGS deficiency is the rarest urea cycle disorder, it is the only one that can be specifically and effectively treated by a drug, N-carbamylglutamate, a stable structural analogous of NAG that activates CPS1.
    explanation: Establishes carglumic acid as the specific curative drug for NAGS deficiency.
  - reference: PMID:38740568
    reference_title: "Use of pure recombinant human enzymes to assess the disease-causing potential of missense mutations in urea cycle disorders, applied to N-acetylglutamate synthase deficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: NAGSD is cured by substitutive therapy with the N-acetyl-L-glutamate analogue N-carbamyl-L-glutamate
    explanation: Confirms NAGS deficiency is cured by substitutive therapy with carglumic acid.
- name: Dietary protein management
  description: 'Although protein restriction was historically used, carbamylglutamate therapy allows most patients to liberalize their diets. However, protein restriction remains an important strategy during illness or disruption of medication access. The maximum safe level of protein intake to prevent hyperammonemia is not yet known.

    '
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
  target_mechanisms:
  - target: Systemic hyperammonemia and glutamine diversion
    treatment_effect: INHIBITS
    description: Protein restriction reduces nitrogen substrate load during illness or when pharmacologic control is uncertain.
    evidence:
    - reference: PMID:38637895
      reference_title: "The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Carbamylglutamate can help patients with NAGS deficiency to liberalize their diets, but the maximum safe level of protein intake to prevent hyperammonemia is not yet known.
      explanation: Supports dietary protein management as an ammonia-prevention strategy.
  evidence:
  - reference: PMID:38637895
    reference_title: "The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Although protein restriction was not prescribed in any cases after carbamylglutamate initiation, two patients continued to self-restrict protein intake.
    explanation: Documents that protein restriction is not routinely needed with carbamylglutamate but remains a consideration.
  - reference: PMID:38637895
    reference_title: "The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Carbamylglutamate can help patients with NAGS deficiency to liberalize their diets, but the maximum safe level of protein intake to prevent hyperammonemia is not yet known.
    explanation: Highlights the evolving role of dietary management alongside pharmacotherapy.
  - reference: PMID:33036647
    reference_title: "Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Management usually consists of treatment with carbamylglutamate, although the reported maintenance dose varied across case reports. Protein restriction was sometimes used in conjunction with carbamylglutamate.
    explanation: Confirms variable use of protein restriction alongside drug therapy.
- name: Nitrogen scavenger therapy
  description: 'Sodium benzoate, sodium phenylacetate, or sodium phenylbutyrate may be used as adjunctive ammonia-lowering agents during acute hyperammonemic crises. These drugs provide alternative nitrogen disposal pathways independent of the urea cycle.

    '
  treatment_term:
    preferred_term: nitrogen scavenger therapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: sodium benzoate
      term:
        id: CHEBI:113455
        label: sodium benzoate
    - preferred_term: sodium phenylbutyrate
      term:
        id: CHEBI:75316
        label: sodium phenylbutyrate
  target_mechanisms:
  - target: Systemic hyperammonemia and glutamine diversion
    treatment_effect: BYPASSES
    description: Nitrogen scavengers route waste nitrogen into urinary excretion pathways that do not require normal urea-cycle flux.
    evidence:
    - reference: PMID:33409766
      reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Ammonia is diverted to the glycine and hippuric acid pathway by benzoate, and to the glutamine and phenylacetylglutamine pathway allowing elimination in the urine without passing through the urea cycle
      explanation: Clinical UCD management review directly supports the bypass mechanism for ammonia scavengers.
  evidence:
  - reference: PMID:33036647
    reference_title: "Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Since its recognition in 1981, NAGS deficiency has been treated with carbamylglutamate with or without other measures (nutritional, ammonia scavengers, dialytic, etc.).
    explanation: Confirms the use of nitrogen scavengers as part of NAGS deficiency management.
  - reference: PMID:33179600
    reference_title: "Primary hyperammonaemia: Current diagnostic and therapeutic strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The acute management includes detoxification of ammonia, which often requires extracorporeal means such as haemodialysis, and the use of intravenous drugs that work as nitrogen scavengers.
    explanation: Supports the use of nitrogen scavengers in acute hyperammonemia management.
- name: Extracorporeal ammonia removal
  description: 'Hemodialysis or continuous venovenous hemofiltration (CVVH) may be required for emergency ammonia removal during severe hyperammonemic crises, particularly when ammonia levels exceed 200 micromol/L or when pharmacological measures are insufficient.

    '
  treatment_term:
    preferred_term: hemodialysis
    term:
      id: MAXO:0000602
      label: hemodialysis
  target_mechanisms:
  - target: Systemic hyperammonemia and glutamine diversion
    treatment_effect: INHIBITS
    description: Dialysis rapidly removes ammonia during severe hyperammonemic crises.
    evidence:
    - reference: PMID:33179600
      reference_title: "Primary hyperammonaemia: Current diagnostic and therapeutic strategies."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: The acute management includes detoxification of ammonia, which often requires extracorporeal means such as haemodialysis, and the use of intravenous drugs that work as nitrogen scavengers.
      explanation: Supports extracorporeal ammonia detoxification as an acute mechanism-directed treatment.
  evidence:
  - reference: PMID:33179600
    reference_title: "Primary hyperammonaemia: Current diagnostic and therapeutic strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The acute management includes detoxification of ammonia, which often requires extracorporeal means such as haemodialysis, and the use of intravenous drugs that work as nitrogen scavengers.
    explanation: Directly supports use of hemodialysis for acute ammonia removal in UCDs.
  - reference: PMID:33409766
    reference_title: "Management of late onset urea cycle disorders-a remaining challenge for the intensivist?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Treatment consists in adapted nutrition, scavenging agents and dialysis. As adults are more susceptible to hyperammonemia, emergent hemodialysis is mandatory before referral to a reference center if ammonia levels are above 200 µmol/l
    explanation: Establishes dialysis threshold and its role in acute UCD management.
- name: Supportive care during acute crises
  description: 'Emergency management of hyperammonemic crises includes cessation of protein intake, reversal of catabolism via high-calorie glucose infusion, correction of dehydration and electrolyte imbalances, and intensive care monitoring. Plans for illness and medication access disruption should be established for all patients.

    '
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
  target_mechanisms:
  - target: Systemic hyperammonemia and glutamine diversion
    treatment_effect: INHIBITS
    description: Crisis plans and anticatabolic supportive measures reduce ammonia generation and prevent recurrent hyperammonemic decompensation.
    evidence:
    - reference: PMID:38637895
      reference_title: "The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Follow-up of patients with NAGS deficiency should include plans for illness and for disruption of carbamylglutamate access, including nutrition management strategies such as protein restriction.
      explanation: NAGS-specific management guidance supports crisis planning to prevent recurrent hyperammonemia.
  target_phenotypes:
  - preferred_term: Hyperammonemia
    term:
      id: HP:0001987
      label: Hyperammonemia
  - preferred_term: Encephalopathy
    term:
      id: HP:0001298
      label: Encephalopathy
  - preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  - preferred_term: Lethargy
    term:
      id: HP:0001254
      label: Lethargy
  - preferred_term: Seizures
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:38637895
    reference_title: "The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Follow-up of patients with NAGS deficiency should include plans for illness and for disruption of carbamylglutamate access, including nutrition management strategies such as protein restriction.
    explanation: Emphasizes the importance of crisis planning and supportive measures.
  - reference: PMID:33179600
    reference_title: "Primary hyperammonaemia: Current diagnostic and therapeutic strategies."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Long-term management of patients with UCDs consists of a low-protein diet, which needs to be balanced and supplemented to avoid deficiencies of essential amino acids, trace elements or vitamins and the use of nitrogen scavengers.
    explanation: Supports comprehensive supportive care for long-term management.
- name: Citrulline and arginine supplementation
  description: 'Supplementation with citrulline or arginine has been reported in some cases of NAGS deficiency to support urea cycle intermediate availability. Arginine is also a positive regulator of NAGS enzyme activity in patients with residual enzyme function.

    '
  treatment_term:
    preferred_term: nutritional supplementation
    term:
      id: MAXO:0000106
      label: nutritional supplementation
    therapeutic_agent:
    - preferred_term: citrulline
      term:
        id: CHEBI:18211
        label: citrulline
    - preferred_term: L-arginine
      term:
        id: CHEBI:16467
        label: L-arginine
  target_mechanisms:
  - target: Impaired arginine-mediated NAGS regulation
    treatment_effect: MODULATES
    description: Arginine supplementation can support residual mammalian NAGS activation while citrulline supports downstream urea-cycle intermediate availability.
    evidence:
    - reference: PMID:27934952
      reference_title: "Effect of arginine on oligomerization and stability of N-acetylglutamate synthase."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: L-arginine inhibits NAGS in bacteria, fungi, and plants and activates NAGS in mammals.
      explanation: Supports L-arginine as a positive regulator of mammalian NAGS activity.
  evidence:
  - reference: PMID:33036647
    reference_title: "Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Supplementation with citrulline, arginine, and sodium benzoate also were reported.
    explanation: Documents the use of citrulline and arginine supplementation in NAGS deficiency management.
- name: Genetic counseling
  description: 'Genetic counseling is essential for affected families given the autosomal recessive inheritance, recurrence risk of 25% for each subsequent pregnancy, and availability of carrier testing and prenatal diagnosis. Molecular confirmation is also critical because NAGS deficiency is clinically indistinguishable from CPS1 deficiency yet has fundamentally different therapeutic implications.

    '
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: MAXO:0000079
      label: genetic counseling
  evidence:
  - reference: PMID:38740568
    reference_title: "Use of pure recombinant human enzymes to assess the disease-causing potential of missense mutations in urea cycle disorders, applied to N-acetylglutamate synthase deficiency."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: NAGSD is cured by substitutive therapy with the N-acetyl-L-glutamate analogue N-carbamyl-L-glutamate, while curative therapy of CPS1D requires liver transplantation. Since their differentiation is done genetically, it is important to ascertain the disease-causing potential of CPS1 and NAGS genetic variants.
    explanation: Emphasizes the critical therapeutic implications of genetic diagnosis, supporting the role of genetic counseling.
  - reference: PMID:33036647
    reference_title: "Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: N-Acetylglutamate synthase (NAGS) deficiency is an extremely rare autosomal recessive metabolic disorder
    explanation: Autosomal recessive inheritance supports the need for genetic counseling.
- name: Carbamylglutamate therapeutic trial
  description: 'A therapeutic trial of carbamylglutamate is recommended for any patient with unexplained hyperammonemia and a proximal urea cycle defect pattern, as it can serve both as a diagnostic tool and as definitive treatment for NAGS deficiency.

    '
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: carglumic acid
      term:
        id: CHEBI:71028
        label: carglumic acid
  target_mechanisms:
  - target: Systemic hyperammonemia and glutamine diversion
    treatment_effect: INHIBITS
    description: Ammonia normalization after carbamylglutamate supports NAGS deficiency and treats the biochemical crisis.
    evidence:
    - reference: PMID:33036647
      reference_title: "Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: DNA testing is the preferred method of diagnosis, although therapeutic trials to assess response of ammonia levels to carbamylglutamate may also be helpful.
      explanation: Therapeutic response of ammonia levels links the trial to the systemic hyperammonemia mechanism.
  evidence:
  - reference: PMID:33036647
    reference_title: "Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: DNA testing is the preferred method of diagnosis, although therapeutic trials to assess response of ammonia levels to carbamylglutamate may also be helpful.
    explanation: Supports use of carbamylglutamate therapeutic trial for diagnosis and treatment.
notes: 'NAGS deficiency is phenotypically identical to CPS1 deficiency and lacks reliable differential biomarkers, making molecular diagnosis essential for targeted treatment decisions. Unlike CPS1 deficiency, which may require liver transplantation, NAGS deficiency can be cured by substitutive therapy with carglumic acid. Medication access interruptions (due to insurance authorization, language barriers, or caregiving limitations) are documented causes of preventable hyperammonemic decompensation. Newborn screening is unreliable for NAGS deficiency due to instability of glutamine markers and low specificity of reduced citrulline levels. A high index of suspicion is needed for late-onset presentations, which can manifest at any age with diverse symptoms including recurrent headaches, behavioral changes, and episodic encephalopathy.

  '

📚

References & Deep Research

Deep Research

1

Falcon ▸

Disease Pathophysiology Research Template

Edison Scientific Literature 49 citations 2026-02-23T23:56:12.797024

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Pathophysiology Research Template

Target Disease

Disease Name: N-acetylglutamate Synthase Deficiency
MONDO ID: (if available)
Category: Genetic

Research Objectives

Please provide a comprehensive research report on the pathophysiology of N-acetylglutamate Synthase Deficiency. Focus on the molecular and cellular mechanisms underlying disease progression.

Required Information

1. Core Pathophysiology

What are the primary pathophysiological mechanisms?
What molecular pathways are dysregulated?
What cellular processes are affected?

2. Key Molecular Players

Genes/Proteins: Which genes are causally involved or implicated?
Chemical Entities: What metabolites, drugs, or small molecules are relevant?
Cell Types: Which cell types are primarily affected?
Anatomical Locations: Which tissues/organs are involved?

3. Biological Processes (for GO annotation)

What biological processes (GO terms) are disrupted?
Consider: signaling pathways, metabolic processes, cellular responses, transport, etc.

4. Cellular Components

Where in the cell do key processes occur?
Consider: organelles, membrane compartments, extracellular space, etc.

5. Disease Progression

What is the sequence of events from initial trigger to clinical manifestation?
Are there distinct stages or phases?

6. Phenotypic Manifestations

What are the key clinical phenotypes?
How do they relate to the underlying mechanisms?

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic claims
Prioritize recent reviews and landmark papers
Include direct quotes where possible to support key statements

Output Format

Structure your response as a narrative that could be used to populate a disease knowledge base entry with: - Pathophysiology description - Gene/protein annotations with ontology terms (HGNC, GO) - Phenotype associations (HP terms) - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Evidence items with PMIDs

Disease pathophysiology research report: N-acetylglutamate synthase (NAGS) deficiency (hyperammonemia due to N-acetylglutamate synthase deficiency)

1) Disease definition, identifiers, and current understanding N-acetylglutamate synthase deficiency (NAGSD; also written NAGS deficiency) is an inherited proximal urea-cycle disorder in which loss of hepatic mitochondrial N-acetylglutamate synthase (NAGS) activity reduces production of N-acetyl-L-glutamate (NAG), the obligate allosteric activator (“cofactor”) required for carbamoyl phosphate synthetase 1 (CPS1) function, thereby impairing ureagenesis and causing hyperammonemia. Clinically, NAGSD is “phenotypically identical” to CPS1 deficiency and lacks “reliable differential biomarkers,” making molecular diagnosis essential for targeted treatment decisions. (gougeard2024useofpure pages 1-2, singh2024theefficacyof pages 1-2)

Disease identifiers • MONDO: MONDO_0009377 (“hyperammonemia due to N-acetylglutamate synthase deficiency”). (erdal2025aminoacidmetabolism pages 10-12) • Orphanet: 927 (“Hyperammonemia due to N-acetylglutamate synthetase deficiency”). (erdal2025aminoacidmetabolism pages 10-12) • OMIM/MIM: 237310 (N-acetylglutamate synthase deficiency). (gougeard2024useofpure pages 1-2)

Epidemiology NAGSD is extremely rare. A 2024 case series states an incidence of “less than one in 2,000,000 live births.” (singh2024theefficacyof pages 1-2) Older estimates (based on relative frequency among UCDs) place it at ~1:3,500,000–7,000,000, and 0.5–1% of urea cycle disorders. (kaabi2016nacetylglutamatesynthasedeficiency pages 1-2)

Inheritance and causal gene NAGSD is autosomal recessive and caused by pathogenic variation in NAGS. (singh2024theefficacyof pages 1-2, kenneson2020presentationandmanagement pages 1-3)

2) Core pathophysiology (molecular → cellular → organ-level) 2.1 Primary biochemical lesion: failure to generate CPS1’s activator (NAG) NAGS catalyzes NAG formation from acetyl-CoA and L-glutamate. In mammals, its major role is to “produce the essential cofactor for carbamoyl phosphate synthetase 1 (CPS1) in the urea cycle.” (shi2015thenacetylglutamatesynthase pages 1-3) NAG is the physiological CPS1 activator: “Cohen's group identified NAG as the natural activator” of CPS1 (carbamoyl phosphate synthesis). (fernandez2015usingrecombinanthuman pages 37-41) Functionally, CPS1 is off without NAG; CPS1 is described as a metabolic switch: “human CPS1 is inactive without NAG,” turning the urea cycle on/off depending on NAG availability. (fernandez2015usingrecombinanthuman pages 34-37) Thus, NAGS loss → low NAG → underactivated CPS1 → reduced carbamoyl phosphate formation → reduced urea cycle flux → hyperammonemia. (singh2024theefficacyof pages 1-2, erdal2025aminoacidmetabolism pages 10-12)

2.2 Subcellular and tissue context NAGS localization: “Mammalian NAGS is found in the mitochondrial matrix of cells of the liver and intestines.” (shi2015thenacetylglutamatesynthase pages 3-6) Urea-cycle zonation: ammonia detoxification through CPS1 occurs in periportal hepatocytes, whereas glutamine synthetase is restricted to perivenous hepatocytes, highlighting the liver’s spatial partitioning of nitrogen handling. (fernandez2015usingrecombinanthuman pages 37-41)

2.3 Dysregulated pathways and cellular processes Core dysregulated pathway: urea cycle / ammonia detoxification. NAGS deficiency “results in dysregulation of ammonia detoxification.” (singh2024theefficacyof pages 1-2) A key regulatory axis is arginine → NAGS → NAG → CPS1. Mammalian NAGS is strongly regulated by L-arginine; in vitro, “Enzymatic activity ... more than doubles (2–5-fold) in the presence of L-arginine.” (shi2015thenacetylglutamatesynthase pages 3-6)

2.4 Secondary systemic and neurological pathophysiology of hyperammonemia Ammonia is the unifying toxic driver: “The common biochemical trait of all UCDs is hyperammonaemia,” and ammonia “can freely diffuse across the blood–brain barrier.” (haberle2020primaryhyperammonaemiacurrent pages 3-4) Brain edema mechanism: brain edema occurs “due to the accumulation of glutamine,” and glutamine “acts as an osmolyte leading to astrocytic water retention.” (haberle2020primaryhyperammonaemiacurrent pages 3-4) Neurotransmission and mitochondrial effects: hyperammonemia-associated glutamine accumulation is linked to “changes of glutamate and N-methyl-d-aspartate (NMDA)-mediated neurotransmission and brain mitochondrial function.” (haberle2020primaryhyperammonaemiacurrent pages 3-4) A complementary ICU-focused synthesis describes the astrocyte mechanism: ammonia is converted to glutamine by glutamine synthase; as glutamine is “the main intracellular osmole of the brain,” its accumulation causes “swelling of astrocytes,” potentially progressing to intracranial hypertension, coma, and death if untreated. (redant2021managementoflate pages 1-3)

3) Key molecular players 3.1 Genes/proteins Causal gene/protein • NAGS (HGNC: NAGS; protein: N-acetylglutamate synthase). (singh2024theefficacyof pages 1-2, gougeard2024useofpure pages 1-2) Key interacting/functional partner • CPS1 (carbamoyl phosphate synthetase 1), the “first and controlling enzyme” of the urea cycle activated by NAG. (gougeard2024useofpure pages 2-4)

Variant-to-function mechanisms (2024 mechanistic advance) A major 2024 experimental study used stabilized recombinant human NAGS to functionally characterize 23 patient nonsynonymous variants, showing that pathogenicity is typically explained by specific biochemical defects including “loss of arginine activation, increased KmGlutamate, active site inactivation, decreased thermal stability, and protein misfolding.” (gougeard2024useofpure pages 1-2) The same study emphasizes loss of arginine activation as a dominant mechanism: “hampered NAGS activation by arginine has emerged as a paramount causative factor of NAGSD.” (gougeard2024useofpure pages 12-14)

3.2 Chemical entities and metabolites (with biomedical relevance) • N-acetyl-L-glutamate (NAG): essential CPS1 activator/cofactor. (shi2015thenacetylglutamatesynthase pages 1-3, fernandez2015usingrecombinanthuman pages 37-41) • Ammonia (NH3/NH4+): toxic metabolite accumulating systemically. (haberle2020primaryhyperammonaemiacurrent pages 3-4) • Glutamine: rises in blood and brain; contributes to cerebral edema via osmotic astrocyte swelling. (haberle2020primaryhyperammonaemiacurrent pages 3-4, redant2021managementoflate pages 1-3) • Citrulline: commonly decreased in proximal UCDs including NAGSD (but can be variable in newer case series). (kenneson2020presentationandmanagement pages 1-3, singh2024theefficacyof pages 2-4) • Orotic acid (urine): typically normal in NAGSD (distinguishing from distal blocks), but mild elevations have been reported in some NAGSD cases. (kenneson2020presentationandmanagement pages 1-3, singh2024theefficacyof pages 2-4) • Substrates: acetyl-CoA and glutamate (NAGS reaction substrates). (shi2015thenacetylglutamatesynthase pages 1-3, haskins2016effectofarginine pages 1-2)

Therapeutic small molecule • N-carbamyl-L-glutamate / carbamylglutamate / carglumic acid (drug; Carbaglu®): bioavailable NAG analog that activates CPS1 and bypasses deficient NAGS. (singh2024theefficacyof pages 1-2, gougeard2024useofpure pages 1-2)

3.3 Cell types and anatomical locations Cell types (CL-aligned) • Hepatocytes, especially periportal hepatocytes (primary site of urea cycle and CPS1 activity). (fernandez2015usingrecombinanthuman pages 37-41, savy2018acutepediatrichyperammonemia pages 1-2) • Astrocytes (brain ammonia detoxification via glutamine synthetase; cell swelling drives edema). (haberle2020primaryhyperammonaemiacurrent pages 3-4, redant2021managementoflate pages 1-3)

Anatomical locations (UBERON-aligned) • Liver (mitochondrial urea cycle compartment; periportal zone). (fernandez2015usingrecombinanthuman pages 37-41) • Intestine (NAGS expression in mitochondrial matrix of intestinal cells). (shi2015thenacetylglutamatesynthase pages 3-6) • Brain (site of ammonia neurotoxicity; cerebral edema/encephalopathy). (haberle2020primaryhyperammonaemiacurrent pages 3-4)

4) Biological processes disrupted (GO-oriented) The following GO-relevant processes are disrupted or centrally involved: • Urea cycle / ureagenesis / ammonia detoxification (loss of CPS1 activation due to low NAG). (shi2015thenacetylglutamatesynthase pages 1-3, singh2024theefficacyof pages 1-2) • N-acetylglutamate biosynthetic process (loss of NAGS activity). (shi2015thenacetylglutamatesynthase pages 1-3) • Regulation of urea cycle flux by allosteric activation (NAG activation of CPS1; arginine activation of NAGS). (fernandez2015usingrecombinanthuman pages 34-37, shi2015thenacetylglutamatesynthase pages 3-6) • Astrocyte glutamine biosynthetic process as compensatory ammonia detoxification in brain, leading to osmotic imbalance/cytotoxic edema. (haberle2020primaryhyperammonaemiacurrent pages 3-4, redant2021managementoflate pages 1-3) • Glutamatergic/NMDA-mediated neurotransmission perturbation and mitochondrial dysfunction in brain during hyperammonemia. (haberle2020primaryhyperammonaemiacurrent pages 3-4)

5) Cellular components (subcellular localization) • Mitochondrial matrix: NAGS localization in liver and intestine; CPS1 abundance in liver mitochondria. (shi2015thenacetylglutamatesynthase pages 3-6, fernandez2015usingrecombinanthuman pages 37-41) • Blood–brain barrier: ammonia crosses into CNS. (haberle2020primaryhyperammonaemiacurrent pages 3-4)

6) Disease progression and sequence of events Initiation/trigger • Genetic NAGS deficiency (autosomal recessive) leads to insufficient NAG production, with susceptibility to hyperammonemia during high nitrogen load or catabolic stress. (kenneson2020presentationandmanagement pages 1-3)

Biochemical progression 1) Reduced NAG → CPS1 underactivation (“inactive without NAG”) → reduced carbamoyl phosphate formation and urea cycle throughput. (fernandez2015usingrecombinanthuman pages 34-37) 2) Systemic ammonia rises (hyperammonemia) with typical proximal-UCD amino-acid patterns (often elevated glutamine, decreased citrulline, normal orotic acid). (kenneson2020presentationandmanagement pages 1-3) 3) CNS toxicity: ammonia crosses BBB; astrocyte glutamine accumulation → astrocyte swelling → cerebral edema; neurotransmission and mitochondrial dysfunction contribute to encephalopathy/seizures. (haberle2020primaryhyperammonaemiacurrent pages 3-4, redant2021managementoflate pages 1-3)

Clinical phases (pragmatic) • Neonatal-onset hyperammonemic encephalopathy is common (majority present in neonatal period), but later-onset presentations occur, including adult-onset in some cases. (kenneson2020presentationandmanagement pages 1-3, cavicchi2018lateonsetnacetylglutamatesynthase pages 1-3) • Acute crises recur particularly with illness, catabolism, dietary protein load, or interruptions in therapy. (kenneson2020presentationandmanagement pages 1-3, singh2024theefficacyof pages 1-2)

7) Phenotypic manifestations (HP-oriented) and mechanistic links Key phenotypes • Hyperammonemia (core biochemical/clinical trait). (haberle2020primaryhyperammonaemiacurrent pages 3-4) • Encephalopathy, seizures, and cerebral edema driven by brain glutamine-mediated osmotic swelling and neurotransmission/mitochondrial effects. (haberle2020primaryhyperammonaemiacurrent pages 3-4, redant2021managementoflate pages 1-3) • Biochemical profile consistent with proximal urea cycle block: elevated plasma glutamine and decreased/low citrulline; urine orotic acid typically normal (but can vary). (kenneson2020presentationandmanagement pages 1-3, singh2024theefficacyof pages 2-4)

Clinical example (neonatal case) A molecularly confirmed neonatal case showed ammonia rising to 1194 µM with “elevated glutamine and glycine” and “undetectable citrulline,” consistent with a proximal urea cycle defect. (kaabi2016nacetylglutamatesynthasedeficiency pages 1-2)

8) Recent developments and latest research (prioritizing 2023–2024) 8.1 2024 mechanistic advance: functional assessment of human NAGS missense variants Gougeard et al. (May 2024) provide a high-resolution genotype-to-mechanism mapping for NAGSD variants using stabilized recombinant human NAGS, identifying multiple mechanistic classes (loss of arginine activation, increased Km for glutamate, misfolding, etc.) and explicitly arguing this approach “outperforms” reliance on bacterial surrogates or in silico prediction for therapeutic guidance. (gougeard2024useofpure pages 1-2, gougeard2024useofpure pages 9-11)

8.2 2024 clinical care advance: carbamylglutamate efficacy and nutrition management Singh et al. (Apr 2024) added seven North American cases and reported that “All patients responded well to carbamylglutamate therapy, as indicated by normalization of plasma ammonia and citrulline, as well as urine orotic acid” when abnormal. (singh2024theefficacyof pages 1-2) They also report that disruptions in drug access can directly precipitate hyperammonemia and poor outcomes, making medication continuity a major implementation priority. (singh2024theefficacyof pages 1-2)

9) Current applications and real-world implementations 9.1 Diagnosis (biochemical + molecular) Biochemical suspicion relies on hyperammonemia with a proximal-UCD amino-acid pattern: “elevated glutamine and decreased citrulline” with urine orotic acid “not elevated.” (kenneson2020presentationandmanagement pages 6-7) Because NAGSD and CPS1 deficiency are clinically indistinguishable and lack “reliable differential biomarkers,” confirmatory genetic testing is critical. (gougeard2024useofpure pages 1-2) A therapeutic trial of carbamylglutamate is recommended for patients with unexplained hyperammonemia: “a therapeutic trial be initiated for any patient with unexplained hyperammonemia.” (kenneson2020presentationandmanagement pages 6-7)

Newborn screening NAGS deficiency is not reliably captured by newborn screening markers; limitations include “instability of glutamine and low specificity and sensitivity of reduced citrulline levels,” and neonatal-onset disease may present before results are available. (kenneson2020presentationandmanagement pages 7-9)

9.2 Acute management Acute hyperammonemia care commonly includes nitrogen scavengers (benzoate, phenylacetate) plus carbamylglutamate in suspected NAGS deficiency. (singh2024theefficacyof pages 1-2) Severe crises may require extracorporeal detoxification (dialysis/CVVH), as illustrated by neonatal and broader UCD management reports. (singh2024theefficacyof pages 4-5, mcnutt2024fatalconsequencesof pages 2-3)

9.3 Targeted disease-modifying therapy: carglumic acid (N-carbamylglutamate) Mechanism Carbamylglutamate (carglumic acid) is a synthetic NAG analog that “activates” CPS1, bypassing deficient NAGS and restoring urea cycle flux. (singh2024theefficacyof pages 1-2) Clinical effect In the 2024 case series, ammonia normalization sometimes required carbamylglutamate after partial response to scavengers; long-term therapy enabled protein liberalization in most patients. (singh2024theefficacyof pages 2-4) Dosing (reported ranges) • Maintenance dosing in case literature: 100–200 mg/kg/day in 3–4 divided doses, with down-titration possible (as low as 10–15 mg/kg/day) to maintain ammonia control (older literature summary). (kaabi2016nacetylglutamatesynthasedeficiency pages 4-4) • In the 2024 series, the lowest daily dose used without recurrent hyperammonemia was 43 mg/kg/day (noting individualization and uncertainty in “maximum safe protein intake”). (singh2024theefficacyof pages 2-4)

Implementation barriers Medication access interruptions are a major, documented cause of preventable decompensation. Singh et al. describe hyperammonemic episodes after disruptions due to insurance authorization and language barriers, and after seizures limited caregivers’ ability to administer medication. (singh2024theefficacyof pages 1-2) Earlier reports highlight limited drug availability in some settings (e.g., tertiary center) affecting treatment continuity. (kaabi2016nacetylglutamatesynthasedeficiency pages 1-2) Broader urea-cycle care also demonstrates that limited health literacy and fragmented access to metabolic supplies/medications can be fatal (case example in another UCD subtype). (mcnutt2024fatalconsequencesof pages 2-3)

10) Relevant statistics and data (recent studies prioritized) Key disease statistics • Incidence: “less than one in 2,000,000 live births.” (Apr 2024) (singh2024theefficacyof pages 1-2) • Presentation age: a review of 98 cases found 58% presented before 1 month of age. (singh2024theefficacyof pages 1-2)

Biomarker/response data (2024 series) Singh et al. report NAGS deficiency presentations with very high ammonia (example 1257 µmol/L), elevated glutamine at presentation in all cases, variable citrulline, and mildly elevated urine orotic acid in some; and that response to carbamylglutamate included normalization of ammonia/citrulline/orotic acid where abnormal. (singh2024theefficacyof pages 2-4, singh2024theefficacyof media 8fe48c65)

Variant mechanism statistics (2024 mechanistic study) Gougeard et al. report that altered arginine activation is common among variants: e.g., “9 of 17 enzymatically active variants ... not activated” by arginine in their assays, and increased Km for glutamate was frequent among active variants. (gougeard2024useofpure pages 12-14, gougeard2024useofpure pages 11-12)

11) Expert opinions and authoritative analyses Guideline perspective The 2019 revision of urea cycle disorder guidelines emphasizes ongoing “under-recognition and delayed diagnosis” despite effective therapies, and aims to harmonize best practices across centers. (haberle2019suggestedguidelinesfor pages 1-3) Mechanistic/therapeutic guidance perspective (2024) Gougeard et al. emphasize that because NAGSD is “cured by substitutive therapy” with N-carbamyl-L-glutamate while CPS1D may require transplantation, accurate molecular diagnosis and functional interpretation of variants are central to therapeutic decision-making. (gougeard2024useofpure pages 1-2)

12) Knowledge-base–ready structured annotations 12.1 Pathophysiology summary (narrative for KB entry) NAGSD is caused by biallelic pathogenic variants in NAGS leading to reduced mitochondrial NAG production in liver (and intestine). NAG is the essential allosteric activator required for CPS1 activity; without NAG, CPS1 is inactive and the urea cycle fails to convert ammonia to urea. Systemic hyperammonemia results, often with elevated glutamine and low/variable citrulline and typically normal urine orotic acid. Ammonia crosses the blood–brain barrier; astrocytes convert ammonia to glutamine, which acts as an osmolyte and drives astrocyte swelling and cerebral edema, with downstream neurotransmission and mitochondrial dysfunction causing encephalopathy and seizures. Targeted therapy with N-carbamyl-L-glutamate (carglumic acid) restores CPS1 activation and can prevent crises, but outcomes depend strongly on early recognition and uninterrupted access to therapy. (fernandez2015usingrecombinanthuman pages 34-37, singh2024theefficacyof pages 1-2, haberle2020primaryhyperammonaemiacurrent pages 3-4)

12.2 Gene/protein annotations (HGNC/GO-style) • NAGS (HGNC symbol: NAGS): enzyme catalyzing N-acetylglutamate synthesis from acetyl-CoA and glutamate; localized to mitochondrial matrix in liver/intestine; regulated by L-arginine. (shi2015thenacetylglutamatesynthase pages 3-6, haskins2016effectofarginine pages 1-2) • CPS1: urea-cycle initiating enzyme requiring NAG as essential activator/cofactor. (shi2015thenacetylglutamatesynthase pages 1-3, fernandez2015usingrecombinanthuman pages 34-37)

12.3 Candidate GO biological processes (labels; IDs not provided in sources) • Urea cycle / ammonia detoxification (disrupted). (singh2024theefficacyof pages 1-2) • N-acetylglutamate biosynthesis (disrupted). (shi2015thenacetylglutamatesynthase pages 1-3) • Allosteric regulation of carbamoyl phosphate synthetase activity (disrupted due to absent NAG). (fernandez2015usingrecombinanthuman pages 34-37) • Astrocyte glutamine biosynthesis and osmotic homeostasis (pathogenic in crisis). (haberle2020primaryhyperammonaemiacurrent pages 3-4)

12.4 Cellular components (labels) • Mitochondrial matrix (primary site of NAGS/CPS1 function). (shi2015thenacetylglutamatesynthase pages 3-6, fernandez2015usingrecombinanthuman pages 37-41) • Blood–brain barrier (ammonia transfer). (haberle2020primaryhyperammonaemiacurrent pages 3-4)

12.5 Phenotype associations (HP-style labels) • Hyperammonemia; hyperammonemic encephalopathy; cerebral edema; seizures; elevated glutamine; decreased/low citrulline; respiratory alkalosis (reported in some). (haberle2020primaryhyperammonaemiacurrent pages 3-4, kenneson2020presentationandmanagement pages 6-7)

12.6 Cell type involvement (CL-style labels) • Hepatocyte (periportal hepatocytes emphasized for urea cycle). (fernandez2015usingrecombinanthuman pages 37-41) • Astrocyte (glutamine synthesis, swelling). (haberle2020primaryhyperammonaemiacurrent pages 3-4)

12.7 Anatomical locations (UBERON-style labels) • Liver; intestine; brain. (shi2015thenacetylglutamatesynthase pages 3-6, haberle2020primaryhyperammonaemiacurrent pages 3-4)

12.8 Chemical entities (CHEBI-style labels) • N-acetyl-L-glutamate (NAG); ammonia; glutamine; citrulline; acetyl-CoA; L-glutamate; N-carbamyl-L-glutamate (carglumic acid). (shi2015thenacetylglutamatesynthase pages 1-3, kaabi2016nacetylglutamatesynthasedeficiency pages 4-4)

13) Evidence items (PMIDs when available; otherwise DOI/URL) Note: Several key 2024 sources retrieved here (Singh 2024; Gougeard 2024) were processed via DOI-linked full text and the PMIDs were not explicitly present in the extracted text. Where PMIDs were available in retrieved evidence, they are listed.

Primary/Recent (2023–2024 prioritized) • Singh RH et al. “The efficacy of Carbamylglutamate impacts the nutritional management of patients with N-Acetylglutamate synthase deficiency.” Orphanet J Rare Dis. Apr 2024. DOI:10.1186/s13023-024-03167-0. URL:https://doi.org/10.1186/s13023-024-03167-0. (singh2024theefficacyof pages 2-4) • Gougeard N et al. “Use of pure recombinant human enzymes to assess the disease-causing potential of missense mutations in urea cycle disorders, applied to N-acetylglutamate synthase deficiency.” J Inherit Metab Dis. May 2024. DOI:10.1002/jimd.12747. URL:https://doi.org/10.1002/jimd.12747. (gougeard2024useofpure pages 1-2) • McNutt MC. “Fatal consequences of limited health literacy in a patient with a rare metabolic disease.” Mol Genet Metab Rep. Jul 2024. DOI:10.1016/j.ymgmr.2024.101121. URL:https://doi.org/10.1016/j.ymgmr.2024.101121. (mcnutt2024fatalconsequencesof pages 2-3)

Guidelines / authoritative reviews • Häberle J et al. “Suggested guidelines for the diagnosis and management of urea cycle disorders: First revision.” J Inherit Metab Dis. May 2019. DOI:10.1002/jimd.12100. URL:https://doi.org/10.1002/jimd.12100. (haberle2019suggestedguidelinesfor pages 1-3) • Häberle J. “Primary Hyperammonaemia: Current Diagnostic and Therapeutic Strategies.” J Mother Child. Jun 2020. DOI:10.34763/jmotherandchild.20202402si.2015.000006. URL:https://doi.org/10.34763/jmotherandchild.20202402si.2015.000006. (haberle2020primaryhyperammonaemiacurrent pages 3-4) • Kenneson A, Singh RH. “Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature.” Orphanet J Rare Dis. Oct 2020. DOI:10.1186/s13023-020-01560-z. URL:https://doi.org/10.1186/s13023-020-01560-z. (kenneson2020presentationandmanagement pages 1-3)

Mechanistic background • Shi D et al. “The N-Acetylglutamate Synthase Family: Structures, Function and Mechanisms.” Int J Mol Sci. Jun 2015. DOI:10.3390/ijms160613004. URL:https://doi.org/10.3390/ijms160613004. (shi2015thenacetylglutamatesynthase pages 1-3) • Haskins N et al. “Effect of arginine on oligomerization and stability of N-acetylglutamate synthase.” Sci Rep. Dec 2016. DOI:10.1038/srep38711. URL:https://doi.org/10.1038/srep38711. (haskins2016effectofarginine pages 1-2) • Savy N et al. “Acute pediatric hyperammonemia: current diagnosis and management strategies.” Hepatic Med. Sep 2018. DOI:10.2147/HMER.S140711. URL:https://doi.org/10.2147/hmer.s140711. (savy2018acutepediatrichyperammonemia pages 1-2)

Clinical exemplar • Al Kaabi EH, El-Hattab AW. “N-acetylglutamate synthase deficiency: Novel mutation associated with neonatal presentation…” Mol Genet Metab Rep. Sep 2016. DOI:10.1016/j.ymgmr.2016.08.004. URL:https://doi.org/10.1016/j.ymgmr.2016.08.004. (kaabi2016nacetylglutamatesynthasedeficiency pages 1-2)

Visual evidence (from 2024 case series) • Singh et al. Table summarizing biochemical findings and treatment/outcomes, including ammonia/citrulline/orotic acid and responses to carbamylglutamate. (singh2024theefficacyof media 8fe48c65, singh2024theefficacyof media adfabe34)

14) Limitations of this synthesis (transparency) • PMIDs were not consistently present in the retrieved full-text extractions for some 2024 papers; this report therefore provides DOIs/URLs for those key sources and includes PMIDs only where available from OpenTargets disease-target evidence or where explicitly present in extracted text. (erdal2025aminoacidmetabolism pages 10-12)

References

(gougeard2024useofpure pages 1-2): Nadine Gougeard, Enea Sancho‐Vaello, M. Leonor Fernández‐Murga, Borja Martínez‐Sinisterra, Badr Loukili‐Hassani, Johannes Häberle, Clara Marco‐Marín, and Vicente Rubio. Use of pure recombinant human enzymes to assess the disease‐causing potential of missense mutations in urea cycle disorders, applied to n‐acetylglutamate synthase deficiency. Journal of Inherited Metabolic Disease, 47:1194-1212, May 2024. URL: https://doi.org/10.1002/jimd.12747, doi:10.1002/jimd.12747. This article has 2 citations and is from a peer-reviewed journal.
(singh2024theefficacyof pages 1-2): Rani H. Singh, Marie-Hélène Bourdages, Angela Kurtz, Erin MacLoed, Chelsea Norman, Suzanne Ratko, Sandra C. van Calcar, and Aileen Kenneson. The efficacy of carbamylglutamate impacts the nutritional management of patients with n-acetylglutamate synthase deficiency. Orphanet Journal of Rare Diseases, Apr 2024. URL: https://doi.org/10.1186/s13023-024-03167-0, doi:10.1186/s13023-024-03167-0. This article has 8 citations and is from a peer-reviewed journal.
(erdal2025aminoacidmetabolism pages 10-12): Ranya Erdal, Kıvanç Birsoy, and Gokhan Unlu. Amino acid metabolism in liver mitochondria: from homeostasis to disease. Metabolites, 15:446, Jul 2025. URL: https://doi.org/10.3390/metabo15070446, doi:10.3390/metabo15070446. This article has 2 citations.
(kaabi2016nacetylglutamatesynthasedeficiency pages 1-2): Eiman H. Al Kaabi and Ayman W. El-Hattab. N-acetylglutamate synthase deficiency: novel mutation associated with neonatal presentation and literature review of molecular and phenotypic spectra. Sep 2016. URL: https://doi.org/10.1016/j.ymgmr.2016.08.004, doi:10.1016/j.ymgmr.2016.08.004. This article has 17 citations.
(kenneson2020presentationandmanagement pages 1-3): Aileen Kenneson and Rani H. Singh. Presentation and management of n-acetylglutamate synthase deficiency: a review of the literature. Orphanet Journal of Rare Diseases, Oct 2020. URL: https://doi.org/10.1186/s13023-020-01560-z, doi:10.1186/s13023-020-01560-z. This article has 23 citations and is from a peer-reviewed journal.
(shi2015thenacetylglutamatesynthase pages 1-3): Dashuang Shi, Norma Allewell, and Mendel Tuchman. The n-acetylglutamate synthase family: structures, function and mechanisms. International Journal of Molecular Sciences, 16:13004-13022, Jun 2015. URL: https://doi.org/10.3390/ijms160613004, doi:10.3390/ijms160613004. This article has 41 citations.
(fernandez2015usingrecombinanthuman pages 37-41): CARMEN DÍEZ FERNÁNDEZ. USING RECOMBINANT HUMAN CARBAMOYL PHOSPHATE SYNTHETASE 1 (CPS1) FOR STUDYING THIS ENZYME'S FUNCTION, REGULATION, PATHOLOGY AND STRUCTURE. PhD thesis, Universitat Politecnica de Valencia, 2015. URL: https://doi.org/10.4995/thesis/10251/52855, doi:10.4995/thesis/10251/52855.
(fernandez2015usingrecombinanthuman pages 34-37): CARMEN DÍEZ FERNÁNDEZ. USING RECOMBINANT HUMAN CARBAMOYL PHOSPHATE SYNTHETASE 1 (CPS1) FOR STUDYING THIS ENZYME'S FUNCTION, REGULATION, PATHOLOGY AND STRUCTURE. PhD thesis, Universitat Politecnica de Valencia, 2015. URL: https://doi.org/10.4995/thesis/10251/52855, doi:10.4995/thesis/10251/52855.
(shi2015thenacetylglutamatesynthase pages 3-6): Dashuang Shi, Norma Allewell, and Mendel Tuchman. The n-acetylglutamate synthase family: structures, function and mechanisms. International Journal of Molecular Sciences, 16:13004-13022, Jun 2015. URL: https://doi.org/10.3390/ijms160613004, doi:10.3390/ijms160613004. This article has 41 citations.
(haberle2020primaryhyperammonaemiacurrent pages 3-4): Johannes Häberle. Primary hyperammonaemia: current diagnostic and therapeutic strategies. Journal of Mother and Child, 24:32-38, Jun 2020. URL: https://doi.org/10.34763/jmotherandchild.20202402si.2015.000006, doi:10.34763/jmotherandchild.20202402si.2015.000006. This article has 22 citations.
(redant2021managementoflate pages 1-3): S. Redant, A. Empain, A. Mugisha, P. Kamgang, R. Attou, P. M. Honoré, and D. De Bels. Management of late onset urea cycle disorders—a remaining challenge for the intensivist? Annals of Intensive Care, Jan 2021. URL: https://doi.org/10.1186/s13613-020-00797-y, doi:10.1186/s13613-020-00797-y. This article has 41 citations and is from a peer-reviewed journal.
(gougeard2024useofpure pages 2-4): Nadine Gougeard, Enea Sancho‐Vaello, M. Leonor Fernández‐Murga, Borja Martínez‐Sinisterra, Badr Loukili‐Hassani, Johannes Häberle, Clara Marco‐Marín, and Vicente Rubio. Use of pure recombinant human enzymes to assess the disease‐causing potential of missense mutations in urea cycle disorders, applied to n‐acetylglutamate synthase deficiency. Journal of Inherited Metabolic Disease, 47:1194-1212, May 2024. URL: https://doi.org/10.1002/jimd.12747, doi:10.1002/jimd.12747. This article has 2 citations and is from a peer-reviewed journal.
(gougeard2024useofpure pages 12-14): Nadine Gougeard, Enea Sancho‐Vaello, M. Leonor Fernández‐Murga, Borja Martínez‐Sinisterra, Badr Loukili‐Hassani, Johannes Häberle, Clara Marco‐Marín, and Vicente Rubio. Use of pure recombinant human enzymes to assess the disease‐causing potential of missense mutations in urea cycle disorders, applied to n‐acetylglutamate synthase deficiency. Journal of Inherited Metabolic Disease, 47:1194-1212, May 2024. URL: https://doi.org/10.1002/jimd.12747, doi:10.1002/jimd.12747. This article has 2 citations and is from a peer-reviewed journal.
(singh2024theefficacyof pages 2-4): Rani H. Singh, Marie-Hélène Bourdages, Angela Kurtz, Erin MacLoed, Chelsea Norman, Suzanne Ratko, Sandra C. van Calcar, and Aileen Kenneson. The efficacy of carbamylglutamate impacts the nutritional management of patients with n-acetylglutamate synthase deficiency. Orphanet Journal of Rare Diseases, Apr 2024. URL: https://doi.org/10.1186/s13023-024-03167-0, doi:10.1186/s13023-024-03167-0. This article has 8 citations and is from a peer-reviewed journal.
(haskins2016effectofarginine pages 1-2): N. Haskins, Amy Mumo, P. H. Brown, M. Tuchman, H. Morizono, and L. Caldovic. Effect of arginine on oligomerization and stability of n-acetylglutamate synthase. Scientific Reports, Dec 2016. URL: https://doi.org/10.1038/srep38711, doi:10.1038/srep38711. This article has 9 citations and is from a peer-reviewed journal.
(savy2018acutepediatrichyperammonemia pages 1-2): Nadia Savy, David Brossier, Catherine Brunel-Guitton, Laurence Ducharme-Crevier, Geneviève Du Pont-Thibodeau, and Philippe Jouvet. Acute pediatric hyperammonemia: current diagnosis and management strategies. Hepatic Medicine : Evidence and Research, 10:105-115, Sep 2018. URL: https://doi.org/10.2147/hmer.s140711, doi:10.2147/hmer.s140711. This article has 105 citations.
(cavicchi2018lateonsetnacetylglutamatesynthase pages 1-3): Catia Cavicchi, Chiara Chilleri, Antonella Fioravanti, Lorenzo Ferri, Francesco Ripandelli, Cinzia Costa, Paolo Calabresi, Paolo Prontera, Francesca Pochiero, Elisabetta Pasquini, Silvia Funghini, Giancarlo La Marca, Maria Donati, and Amelia Morrone. Late-onset n-acetylglutamate synthase deficiency: report of a paradigmatic adult case presenting with headaches and review of the literature. International Journal of Molecular Sciences, 19:345, Jan 2018. URL: https://doi.org/10.3390/ijms19020345, doi:10.3390/ijms19020345. This article has 11 citations.
(gougeard2024useofpure pages 9-11): Nadine Gougeard, Enea Sancho‐Vaello, M. Leonor Fernández‐Murga, Borja Martínez‐Sinisterra, Badr Loukili‐Hassani, Johannes Häberle, Clara Marco‐Marín, and Vicente Rubio. Use of pure recombinant human enzymes to assess the disease‐causing potential of missense mutations in urea cycle disorders, applied to n‐acetylglutamate synthase deficiency. Journal of Inherited Metabolic Disease, 47:1194-1212, May 2024. URL: https://doi.org/10.1002/jimd.12747, doi:10.1002/jimd.12747. This article has 2 citations and is from a peer-reviewed journal.
(kenneson2020presentationandmanagement pages 6-7): Aileen Kenneson and Rani H. Singh. Presentation and management of n-acetylglutamate synthase deficiency: a review of the literature. Orphanet Journal of Rare Diseases, Oct 2020. URL: https://doi.org/10.1186/s13023-020-01560-z, doi:10.1186/s13023-020-01560-z. This article has 23 citations and is from a peer-reviewed journal.
(kenneson2020presentationandmanagement pages 7-9): Aileen Kenneson and Rani H. Singh. Presentation and management of n-acetylglutamate synthase deficiency: a review of the literature. Orphanet Journal of Rare Diseases, Oct 2020. URL: https://doi.org/10.1186/s13023-020-01560-z, doi:10.1186/s13023-020-01560-z. This article has 23 citations and is from a peer-reviewed journal.
(singh2024theefficacyof pages 4-5): Rani H. Singh, Marie-Hélène Bourdages, Angela Kurtz, Erin MacLoed, Chelsea Norman, Suzanne Ratko, Sandra C. van Calcar, and Aileen Kenneson. The efficacy of carbamylglutamate impacts the nutritional management of patients with n-acetylglutamate synthase deficiency. Orphanet Journal of Rare Diseases, Apr 2024. URL: https://doi.org/10.1186/s13023-024-03167-0, doi:10.1186/s13023-024-03167-0. This article has 8 citations and is from a peer-reviewed journal.
(mcnutt2024fatalconsequencesof pages 2-3): Markey C. McNutt. Fatal consequences of limited health literacy in a patient with a rare metabolic disease. Molecular Genetics and Metabolism Reports, Jul 2024. URL: https://doi.org/10.1016/j.ymgmr.2024.101121, doi:10.1016/j.ymgmr.2024.101121. This article has 0 citations.
(kaabi2016nacetylglutamatesynthasedeficiency pages 4-4): Eiman H. Al Kaabi and Ayman W. El-Hattab. N-acetylglutamate synthase deficiency: novel mutation associated with neonatal presentation and literature review of molecular and phenotypic spectra. Sep 2016. URL: https://doi.org/10.1016/j.ymgmr.2016.08.004, doi:10.1016/j.ymgmr.2016.08.004. This article has 17 citations.
(singh2024theefficacyof media 8fe48c65): Rani H. Singh, Marie-Hélène Bourdages, Angela Kurtz, Erin MacLoed, Chelsea Norman, Suzanne Ratko, Sandra C. van Calcar, and Aileen Kenneson. The efficacy of carbamylglutamate impacts the nutritional management of patients with n-acetylglutamate synthase deficiency. Orphanet Journal of Rare Diseases, Apr 2024. URL: https://doi.org/10.1186/s13023-024-03167-0, doi:10.1186/s13023-024-03167-0. This article has 8 citations and is from a peer-reviewed journal.
(gougeard2024useofpure pages 11-12): Nadine Gougeard, Enea Sancho‐Vaello, M. Leonor Fernández‐Murga, Borja Martínez‐Sinisterra, Badr Loukili‐Hassani, Johannes Häberle, Clara Marco‐Marín, and Vicente Rubio. Use of pure recombinant human enzymes to assess the disease‐causing potential of missense mutations in urea cycle disorders, applied to n‐acetylglutamate synthase deficiency. Journal of Inherited Metabolic Disease, 47:1194-1212, May 2024. URL: https://doi.org/10.1002/jimd.12747, doi:10.1002/jimd.12747. This article has 2 citations and is from a peer-reviewed journal.
(haberle2019suggestedguidelinesfor pages 1-3): Johannes Häberle, Alberto Burlina, Anupam Chakrapani, Marjorie Dixon, Daniela Karall, Martin Lindner, Hanna Mandel, Diego Martinelli, Guillem Pintos‐Morell, René Santer, Anastasia Skouma, Aude Servais, Galit Tal, Vicente Rubio, Martina Huemer, and Carlo Dionisi‐Vici. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision. Journal of Inherited Metabolic Disease, 42:1192-1230, May 2019. URL: https://doi.org/10.1002/jimd.12100, doi:10.1002/jimd.12100. This article has 544 citations and is from a peer-reviewed journal.
(singh2024theefficacyof media adfabe34): Rani H. Singh, Marie-Hélène Bourdages, Angela Kurtz, Erin MacLoed, Chelsea Norman, Suzanne Ratko, Sandra C. van Calcar, and Aileen Kenneson. The efficacy of carbamylglutamate impacts the nutritional management of patients with n-acetylglutamate synthase deficiency. Orphanet Journal of Rare Diseases, Apr 2024. URL: https://doi.org/10.1186/s13023-024-03167-0, doi:10.1186/s13023-024-03167-0. This article has 8 citations and is from a peer-reviewed journal.

N-Acetylglutamate Synthase Deficiency

Ask OpenScientist

OpenScientist Report

Classifications

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Biochemical Markers

Source YAML

References & Deep Research

Deep Research

Disease Pathophysiology Research Template

Target Disease

Research Objectives

Required Information

1. Core Pathophysiology

2. Key Molecular Players

3. Biological Processes (for GO annotation)

4. Cellular Components

5. Disease Progression

6. Phenotypic Manifestations

Citation Requirements

Output Format